ClinicalTrials.gg
CompletedNCT04315298Updated Sep 23, 2021Results posted

Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19

A Phase 2/3 interventional study of Sarilumab and Placebo in COVID-19, sponsored by Regeneron Pharmaceuticals. Completed at 62 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-09-23.

Sponsored by Regeneron Pharmaceuticals · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
1,912
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in COVID-19 by Regeneron Pharmaceuticals — none open to participants now, none under way, none of them phase 3. COVID-19 · Regeneron Pharmaceuticals.

Enrollment
3rd of 12
1,912 · median 57
Started
2020
with 4 others
Phase 2/3
Only one
of the 13
Registered
1st of 13
by date

Among the 13 studies in COVID-19 by Regeneron Pharmaceuticals, this one is the 3rd largest by enrollment of the 12 interventional ones that give a count, is one of 5 that started in 2020, is the only one in phase 2/3, and was the 1st registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

None of the 13 studies in COVID-19 by Regeneron Pharmaceuticals is open now. The open studies under COVID-19, anywhere →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies in COVID-19 by Regeneron Pharmaceuticals as a file.
02

Study summary

Phase 2:

The primary objective of the study is to evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospitalized with COVID-19 regardless of disease severity strata.

Phase 3 Cohort 1:

The primary objective of the study is to evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospitalized with critical COVID-19 receiving mechanical ventilation at baseline.

Phase 3 Cohort 2:

The primary objective of the study is to evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospitalized with COVID-19 receiving mechanical ventilation at baseline.

Read the detailed description

Phase 2 and Phase 3 Cohort 1 completed. Cohorts 2 and 3 terminated early based on Phase 3 Cohort 1 results.

03

Conditions studied

  • COVID-19

Keywords

  • COVID-19
  • SARS-COV-2
  • coronavirus
  • IL-6
  • sarilumab
  • acute respiratory distress syndrome
  • treatment
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Laboratory-confirmed SARS-CoV-2 infection as determined by polymerase chain reaction (PCR), result from any specimen (or other commercial or public health assay) within 2 weeks prior to randomization and no alternative explanation for current clinical condition
  • Hospitalized with illness of any duration with evidence of pneumonia, requires supplemental oxygen and/or assisted ventilation and meets one of the following:
  • Phase 2 and Phase 3 Cohort 1:

Meets 1 of the following criteria at baseline:

  • Severe disease OR
  • Critical disease OR
  • Multi-system organ dysfunction OR
  • Phase 3 Cohort 2:

Patients must be receiving mechanical ventilation to treat respiratory failure due to COVID-19

  • Phase 3 Cohort 3:

Patients must be receiving supplemental oxygen to treat hypoxemia delivered by one of the following devices:

  • Non-rebreather mask, OR
  • High-flow device with at least 50% FiO2, OR
  • Non-invasive positive pressure ventilator
  • Ability to provide signed by study patient or legally acceptable representative
  • Willingness and ability to comply with study-related procedures/assessments

Key Exclusion Criteria:

  • In the opinion of the investigator, not expected to survive for more than 48 hours from screening
  • Presence of any of the following abnormal laboratory values at screening: (ANC) less than 2000 mm3, (AST) or alanine aminotransferase (ALT) > 5 x (ULN), \<50,000 per mm3
  • Treatment with anti-IL 6, anti-IL-6R antagonists, or with Janus kinase inhibitors (JAKi) in the past 30 days or plans to receive during the study period
  • Current treatment with the simultaneous combination of leflunomide and methotrexate
  • Known active tuberculosis (TB), history of incompletely treated TB, suspected or known extrapulmonary TB, suspected or known systemic bacterial or fungal infections
  • Participation in a double-blind clinical research study evaluating an product (IP) or therapy within 3 months and less than 5 half-lives of IP prior to the screening visit (The use of remdesivir, hydroxychloroquine, or other treatments being used for COVID-19 treatments in the context of an open-label study, Emergency Use Authorization (EUA), compassionate use protocol or open-label use is permitted)
  • Any physical examination findings, and/or history of any illness, concomitant medications or recent that, in the opinion of the study investigator, might confound the results of the study or pose an additional risk to the patient by their participation in the study
  • Known systemic to sarilumab or the of the drug product
  • Phase 3 Cohort 2 and Cohort 3 only:
  • Known or suspected history of immunosuppression or immunodeficiency disorder
  • Patients who require renal replacement therapy for acute kidney injury at randomization or who required renal replacement therapy within 72 hours prior to randomization
  • Patients who have circulatory shock requiring vasopressors at randomization or within 24 hours prior to randomization
  • Use of extracorporeal life support (eg, ECMO) or, in the opinion of the investigator, there is a high likelihood that extracorporeal life support will be initiated within 48 hours after randomization

NOTE: Other protocol defined inclusion / exclusion criteria may apply

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,912 participants (actual)

Study arms

  • Experimental
    Sarilumab 200mg IV (P2)

    Phase 2

    Drug: Sarilumab · Drug: Placebo

  • Experimental
    Sarilumab 200mg IV (P3:C1)

    Phase 3: Cohort 1

    Drug: Sarilumab · Drug: Placebo

  • Experimental
    Sarilumab 400mg IV (P2)

    Phase 2

    Drug: Sarilumab · Drug: Placebo

  • Experimental
    Sarilumab 400mg IV (P3:C1)

    Phase 3: Cohort 1

    Drug: Sarilumab · Drug: Placebo

  • Experimental
    Sarilumab 800mg IV (P3:C2)

    Phase 3: Cohort 2

    Drug: Sarilumab · Drug: Placebo

  • Experimental
    Sarilumab 800mg IV (P3: C3)

    Phase 3: Cohort 3

    Drug: Sarilumab · Drug: Placebo

Interventions

  • Single or multiple intravenous (IV) doses of sarilumab. Additional doses may be administered if the patient meets protocol defined criteria.

    Also known as: Kevzara®, REGN88, SAR153191

  • DrugPlacebo

    Single or multiple intravenous (IV) doses of placebo to match sarilumab administration

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in CRP Levels at Day 4 in Participants With Serum IL-6 Level Greater Than the ULN (Phase 2)

    Percent Change from Baseline in C-Reactive Protein (CRP) Levels at Day 4 in Participants with Serum Interleukin 6 (IL-6) Level Greater than the Upper Limit of Normal (ULN) Least Squares (LS) means estimate of percent change from baseline at Day 4 (raw scale) for each treatment group is based on the Analysis of Covariance (ANCOVA) model. It is defined as anti-log of the estimate of dependent variable minus 1, i.e., (exp\[ln(CRP at day 4/Baseline CRP)\]-1. Negative numbers imply improvement in CRP.

    Time frame: Baseline and Day 4

  2. Percentage of Participants With at Least a 1-point Improvement in Clinical Status From Baseline to Day 22 Using the 7-point Ordinal Scale in Participants With Critical COVID-19 Receiving Mechanical Ventilation at Baseline (Phase 3 Cohort 1)

    The ordinal scale is an assessment of the clinical status of a participant. The 7-point ordinal scale is as follows: 1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity

    Time frame: Day 22

  3. Percentage of Participants With at Least 1-point Improvement in Clinical Status Using the 7-point Ordinal Scale in Participants With COVID-19 Receiving Mechanical Ventilation at Baseline (Phase 3 Cohort 2)

    The ordinal scale is an assessment of the clinical status of a participant The 7-point ordinal scale is as follows: 1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity

    Time frame: Day 22

Secondary outcomes

  1. Time to Improvement (2 Points) in Clinical Status Assessment in Severe or Critical Patients With Serum IL-6 Levels Greater Than the Upper Limit of Normal (Phase 2)

    Time to improvement (2 points) in clinical status assessment on the 7-point ordinal scale in severe or critical participants with serum IL-6 levels greater than the upper limit of normal (ULN). The ordinal scale is an assessment of the clinical status of a patient. The 7-point ordinal scale is as follows: 1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity

    Time frame: Up to Day 29

  2. Time to Improvement (2 Points) in Clinical Status Assessment in Severe or Critical Patients With All Serum IL-6 Levels (Phase 2)

    Time to improvement (2 points) in clinical status assessment on the 7-point ordinal scale in severe or critical participants with all serum IL-6 levels. The 7-point ordinal scale is as follows: 1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity

    Time frame: Up to Day 29

  3. Time to Resolution of Fever for at Least 48 Hours Without Antipyretics or Until Discharge, Whichever is Sooner, in Patients With Documented Fever at Baseline (Phase 2)

    Time to resolution of fever for at least 48 hours without antipyretics or until discharge, whichever is sooner, in patients with documented fever ≥38°C (oral), ≥38.4°C (rectal or tympanic), or ≥37.6°C (temporal or axillary) at Baseline. Resolution of fever is defined as postbaseline body temperature \<37.2°C (oral), or \<37.6°C (rectal or tympanic) or \<36.8°C (temporal or axillary).

    Time frame: Up to Day 29

  4. Time to Resolution of Fever for at Least 48 Hours Without Antipyretics by Clinical Severity (Phase 2)

    Resolution of fever is defined as body temperature \<=36.8 C (axilla or temporal) or\<= 37.2 C (oral) or \<37.6 C (rectal or tympanic) for at least 48 hours without antipyretics or until discharge. Resolution of fever is defined only in participants with presence of fever at baseline.

    Time frame: Up to day 29

  5. Time to Resolution of Fever for at Least 48 Hours Without Antipyretics or Until Discharge, Whichever is Sooner, by Baseline IL-6 Levels (Phase 2)

    Resolution of fever is defined as body temperature \<=36.8 C (axilla or temporal) or\<= 37.2 C (oral) or \<37.6 C (rectal or tympanic) for at least 48 hours without antipyretics or until discharge, by baseline IL-6 levels. Resolution of fever is defined only in participants with presence of fever at baseline.

    Time frame: Up to Day 29

  6. Time to Improvement in Oxygenation for at Least 48 Hours (Phase 2)

    Improvement in oxygenation defined as increase in SpO2/FiO2 of 50 or greater compared to the nadir SpO2/FiO2

    Time frame: Up to day 29

  7. Time to Improvement in Oxygenation for at Least 48 Hours by Baseline IL-6 Levels (Phase 2)

    Time to Improvement defined as increase in SpO2/FiO2 of 50 or greater compared to the nadir SpO2/FiO2

    Time frame: Up to day 29

  8. Time to Resolution of Fever and Improvement in Oxygenation for at Least 48 Hours (Phase 2)

    Resolution of fever defined as postbaseline body temperature \<37.2°C (oral), or \<37.6°C (rectal or tympanic) or \<36.8°C (temporal or axillary) Improvement in oxygenation defined as increase in SpO2/FiO2 of 50 or greater compared to the nadir SpO2/FiO2

    Time frame: Up to day 29

  9. Percentage of Participants in Each Clinical Status Category Using the 7-point Ordinal Scale up to Day 29 (Phase 2)

    Percentage of participants in each clinical status category using the 7-point ordinal scale from Baseline (Day 1) up to Day 29. The 7-point ordinal scale is as follows: 1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity

    Time frame: Days 1, 3, 5, 8, 11, 15 and 29

  10. Time to Discharge or to a National Early Warning Score 2 (NEWS2) of ≤2 and Maintained for 24 Hours (Phase 2)

    NEWS2 was used to standardize assessment of acute-illness severity, track clinical condition of participants and to alert clinical teams to participant deterioration. NEWS2 score was based on 7 clinical parameters: respiration rate, oxygen saturation, supplemental oxygen, systolic blood pressure, pulse rate, level of consciousness, and temperature. A score of 0, 1, 2, and 3 was allocated to each parameter except supplemental oxygen (a score of 0 or 1 was allocated) and level of consciousness (a score of 0 or 3 was allocated), where 0 = normal health condition to 3 = worst health condition; higher score indicated more severity. All scores were summed to get an aggregate score. Aggregate NEWS2 score ranged from 0 to 19, with higher scores meaning more severity/higher risk: low risk (score 0 to 4); low to medium risk (score of 3 in any individual parameter); medium risk (score 5 to 6); high risk (score 7 to 19).

    Time frame: Up to day 29

  11. Change From Baseline in NEWS2 Scoring System (Phase 2)

    NEWS2 was used to standardize assessment of acute-illness severity, track clinical condition of participants and to alert clinical teams to participant deterioration. NEWS2 score was based on 7 clinical parameters: respiration rate, oxygen saturation, supplemental oxygen, systolic blood pressure, pulse rate, level of consciousness, and temperature. A score of 0, 1, 2, and 3 was allocated to each parameter except supplemental oxygen (a score of 0 or 1 was allocated) and level of consciousness (a score of 0 or 3 was allocated), where 0 = normal health condition to 3 = worst health condition; higher score indicated more severity. All scores were summed to get an aggregate score. Aggregate NEWS2 score ranged from 0 to 19, with higher scores meaning more severity/higher risk: low risk (score 0 to 4); low to medium risk (score of 3 in any individual parameter); medium risk (score 5 to 6); high risk (score 7 to 19).

    Time frame: Days 3, 5, 8, 11, 15 and 29

  12. Number of Days With Fever (Phase 2)

    Defined as ≥38°C (oral), ≥38.4°C (rectal or tympanic) or ≥37.6°C (temporal or axillary)

    Time frame: Up to Day 29

  13. Percentage of Participants Alive, Off Oxygen (Phase 2)

    Time frame: At Day 29

  14. Number of Days of Resting Respiratory Rate >24 Breaths/Min (Phase 2)

    Time frame: Up to day 29

  15. Number of Days With Hypoxemia (Phase 2)

    Time frame: Up to day 29

  16. Number of Days of Supplemental Oxygen Use (Phase 2)

    Time frame: Up to day 29

  17. Time to Saturation ≥94% on Room Air (Phase 2)

    Time frame: Up to day 29

  18. Number of Ventilator Free Days (Phase 2)

    Summary of Ventilator-free days during study in Participants using Invasive Mechanical Ventilation at Baseline

    Time frame: Up to Day 22

  19. Number of Participants Who Initiated Mechanical Ventilation After Baseline (Phase 2)

    Time frame: Up to Day 29

  20. Number of Days in an Intensive Care Unit (ICU) in Participants Who Were Not in ICU at Baseline (Phase 2)

    Time frame: Up to Day 29

  21. Number of Days of Hospitalization Among Survivors (Phase 2)

    Time frame: Up to day 29

  22. Number of Deaths Due to Any Cause

    Number of deaths due to any cause (All-Cause Mortality)

    Time frame: Up to day 60

  23. Percentage of Participants With at Least 1-point Improvement in Clinical Status Using the 7-point Ordinal Scale in Participants With Critical COVID-19 (Phase 3 Cohort 1: Critical ITT)

    The ordinal scale is an assessment of the clinical status of a participant. The 7-point ordinal scale is as follows: 1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity

    Time frame: Day 22

  24. Percentage of Participants Who Recover (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)

    Percentage of Participants Who Recover (Discharged, or Alive without Supplemental Oxygen Use or at Pre-COVID Oxygen Use) at Day 22

    Time frame: Day 22

  25. Percentage of Participants Who Recover (Phase 3 Cohort 1: Critical ITT)

    Percentage of Participants Who Recover (Discharged, or Alive without Supplemental Oxygen Use or at Pre-COVID Oxygen Use) at Day 22

    Time frame: Day 22

  26. Percentage of Participants Who Die (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)

    Percentage of Participants who die through Day 29 and Day 60

    Time frame: Up to Day 29 and Day 60

  27. Percentage of Participants Who Die (Phase 3 Cohort 1: Critical ITT)

    Percentage of Participants who die through Day 29 and Day 60

    Time frame: Up to Day 29 and Day 60

  28. Percentage of Participants Alive Not Receiving Mechanical Ventilation or ECMO at Day 22 (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)

    Percentage of participants alive not receiving mechanical ventilation or ECMO at Day 22 (Phase 3 Cohort 1)

    Time frame: At Day 22

  29. Percentage of Participants With at Least a 2-point Improvement in Clinical Status From Baseline to Day 22 Using the 7-point Ordinal Scale (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)

    Percentage of participants with at least a 2-point improvement in clinical status from baseline to Day 22 using the 7-point ordinal scale. The ordinal scale is an assessment of the clinical status of a participant. The 7-point ordinal scale is as follows: 1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity

    Time frame: At Day 22

  30. Percentage of Participants Alive Not Receiving Mechanical Ventilation or ECMO at Day 22 (Phase 3 Cohort 1: Critical ITT)

    Percentage of participants alive not receiving mechanical ventilation or ECMO at Day 22 (Phase 3 Cohort 1)

    Time frame: At Day 22

  31. Percentage of Participants With at Least a 2-point Improvement in Clinical Status From Baseline to Day 22 Using the 7-point Ordinal Scale (Phase 3 Cohort 1: Critical ITT)

    Percentage of participants with at least a 2-point improvement in clinical status from baseline to Day 22 using the 7-point ordinal scale. The ordinal scale is an assessment of the clinical status of a participant. The 7-point ordinal scale is as follows: 1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity

    Time frame: At Day 22

  32. Time to at Least 1-point Improvement in Clinical Status Assessment on the 7-point Ordinal Scale (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)

    The ordinal scale is an assessment of the clinical status of a participant. The 7-point ordinal scale is as follows: 1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity

    Time frame: Up to day 29

  33. Time to at Least 1-point Improvement in Clinical Status Assessment on the 7-point Ordinal Scale (Phase 3 Cohort 1: Critical ITT)

    The ordinal scale is an assessment of the clinical status of a participant. The 7-point ordinal scale is as follows: 1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity

    Time frame: Up to day 29

  34. Time to at Least 1-point Improvement in Clinical Status Assessment on the 7-point Ordinal Scale (Phase 3 Cohort 2)

    The ordinal scale is an assessment of the clinical status of a participant. The 7-point ordinal scale is as follows: 1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity

    Time frame: Up to day 29

  35. Time to at Least 2-point Improvement in Clinical Status Assessment on the 7-point Ordinal Scale (Phase 3 Cohort 1)

    The ordinal scale is an assessment of the clinical status of a participant. The 7-point ordinal scale is as follows: 1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity

    Time frame: Up to day 29

  36. Time to at Least 2-point Improvement in Clinical Status Assessment on the 7-point Ordinal Scale (Phase 3 Cohort 1: Critical ITT)

    The ordinal scale is an assessment of the clinical status of a participant. The 7-point ordinal scale is as follows: 1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity

    Time frame: Up to day 29

  37. Percentage of Participants Receiving Mechanical Ventilation or ECMO at Day 22 (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)

    Time frame: Day 22

  38. Percentage of Participants Receiving Mechanical Ventilation or ECMO at Day 22 (Phase 3 Cohort 1: Critical ITT)

    Time frame: Day 22

  39. Percentage of Patients Discharged and Alive (Phase 3 Cohort 1)

    Percentage of Patients Discharged and Alive at Day 22

    Time frame: At Day 22

  40. Percentage of Participants Discharged and Alive at Day 22 (Phase 3 Cohort 1: Critical ITT)

    Percentage of Participants Discharged and Alive at Day 22

    Time frame: At Day 22

  41. Time to Recovery (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)

    Phase 3 Cohort 1 Time to Recovery (Discharged, or Alive without Supplemental Oxygen Use or at Pre-COVID Oxygen Use)

    Time frame: Up to day 29

  42. Time to Recovery (Phase 3 Cohort 1: Critical ITT)

    Phase 3 Cohort 1 Time to Recovery (Discharged, or Alive without Supplemental Oxygen Use or at Pre-COVID Oxygen Use)

    Time frame: Up to day 29

  43. Time to Recovery (Phase 3 Cohort 2)

    Time to Recovery (Discharged, or Alive without Supplemental Oxygen Use or at Pre-COVID Oxygen Use)

    Time frame: Up to day 29

  44. Time to Death (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)

    Phase 3 Cohort 1 Time to Death (All-Cause Mortality)

    Time frame: Up to day 60

  45. Time to Death (Phase 3 Cohort 1: Critical ITT)

    Time to Death (All-Cause Mortality)

    Time frame: Up to day 60

  46. Time to Death (Phase 3 Cohort 2)

    Time to Death (All-Cause Mortality)

    Time frame: Up to day 60

  47. Number of Ventilator-Free Days (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)

    Number of Ventilator-Free days up to Day 29 (Phase 3 Cohort 1)

    Time frame: Days 8, 15, 22 and 29

  48. Number of Ventilator-Free Days (Phase 3 Cohort 1: Critical ITT)

    Number of Ventilator-Free days up to Day 29 (Phase 3 Cohort 1)

    Time frame: Days 8, 15, 22 and 29

  49. Number of Days of Hospitalization Among Survivors (Phase 3 Cohort 1)

    Number of days of hospitalization among survivors (Phase 3 Cohort 1)

    Time frame: Days 8, 15, 22 and 29

  50. Number of Days of Hospitalization Among Survivors (Phase 3 Cohort 1: Critical ITT)

    Number of days of hospitalization among survivors (Phase 3 Cohort 1: Critical ITT population)

    Time frame: Days 8, 15, 22 and 29

  51. Number of Participants With Any Serious Adverse Event

    Time frame: Up to day 60

  52. Number of Participants With Grade 4 Neutropenia (ANC <500/mm3)

    Grade 4 Neutropenia defined as Absolute Neutrophil Count (ANC) of less than 500 per cubic millimeter(mm3)

    Time frame: Up to day 60

  53. Number of Participants With Severe or Life-threatening Bacterial, Invasive Fungal, or Opportunistic Infection

    Time frame: Up to day 60

  54. Number of Participants With Grade 4 Neutropenia and Concurrent Invasive Infection

    Time frame: Up to day 60

  55. Number of Participants With Grade >=2 Infusion Related Reactions

    Time frame: Up to day 60

  56. Number of Participants With Grade >=2 Hypersensitivity Reactions

    Time frame: Up to day 60

  57. Number of Participants With Gastrointestinal Perforation

    Time frame: Up to day 60

  58. Mean Observed Leukocyte Values Across Study Days (Phase 2)

    Time frame: Days 1, 4, 15 and 29

  59. Mean Observed Leukocyte Values Across Study Days (Phase 3)

    Time frame: Days 1, 4, 15 and 29

  60. Mean Observed Hemoglobin Values Across Study Days (Phase 2)

    Time frame: Days 1, 4, 15 and 29

  61. Mean Observed Hemoglobin Values Across Study Days (Phase 3)

    Time frame: Days 1, 4, 15 and 29

  62. Mean Observed Platelet Count Across Study Days (Phase 2)

    Time frame: Days 1, 4, 15 and 29

  63. Mean Observed Platelet Count Across Study Days (Phase 3)

    Time frame: Days 1, 4, 15 and 29

  64. Mean Observed Total Bilirubin Values Across Study Days (Phase 2)

    Time frame: Days 1, 4, 15 and 29

  65. Mean Observed Total Bilirubin Across Study Days (Phase 3)

    Time frame: Days 1, 4, 15 and 29

  66. Mean Observed Aspartate Aminotransferase Values Across Study Days (Phase 2)

    Time frame: Days 1, 4, 15 and 29

  67. Mean Observed Aspartate Aminotransferase Values Across Study Days (Phase 3)

    Time frame: Days 1, 4, 15 and 29

  68. Mean Observed Alanine Aminotransferase Values Across Study Days (Phase 2)

    Time frame: Days 1, 4, 15 and 29

  69. Mean Observed Alanine Aminotransferase Values Across Study Days (Phase 3)

    Time frame: Days 1, 4, 15 and 29

  70. Mean Observed Creatinine Values Across Study Days (Phase 2)

    Time frame: Days 1, 4, 15 and 29

  71. Mean Observed Creatinine Values Across Study Days (Phase 3)

    Time frame: Days 1, 4, 15 and 29

07

Results

Posted Sep 23, 2021

Participant flow

Participant flow — Overall Study
MilestonePhase 2: PlaceboPhase 2: Sarilumab 200mg IVPhase 2: Sarilumab 400mg IVPhase 3 Cohort 1: Placebo - CriticalPhase 3 Cohort 1: Sarilumab 200mg IV - CriticalPhase 3 Cohort 1: Sarilumab 400mg IV - CriticalPhase 3 Cohort 1: Placebo - SeverePhase 3 Cohort 1: Sarilumab 200mg IV - SeverePhase 3 Cohort 1: Sarilumab 400mg IV - SeverePhase 3 Cohort 1: Placebo - MSODPhase 3 Cohort 1: Sarilumab 200mg IV - MSODPhase 3 Cohort 1: Sarilumab 400mg IV - MSODPhase 3 Cohort 1: Placebo - ImmunocompromisedPhase 3 Cohort 1: Sarilumab 200mg IV - ImmunocompromisedPhase 3 Cohort 1: Sarilumab 400mg IV - ImmunocompromisedPhase 3 Cohort 2: PlaceboPhase 3 Cohort 2: Sarilumab 800mg IVPhase 3 Cohort 3: PlaceboPhase 3 Cohort 3: Sarilumab 800mg IV
Started901871801702423387014013746959281215151662
Completed611171251011572095211110129535158991352
Not completed29705569851291829361742413466310
Withdrew: Withdrawal by subject0002220111000000000
Withdrew: Physician decision0000100000000000000
Withdrew: Lost to follow-up510681213916140210002000
Withdrew: Death2460495970114912211640403464310

Outcome measures

PrimaryPercent Change From Baseline in CRP Levels at Day 4 in Participants With Serum IL-6 Level Greater Than the ULN (Phase 2)

Percent Change from Baseline in C-Reactive Protein (CRP) Levels at Day 4 in Participants with Serum Interleukin 6 (IL-6) Level Greater than the Upper Limit of Normal (ULN) Least Squares (LS) means estimate of percent change from baseline at Day 4 (raw scale) for each treatment group is based on the Analysis of Covariance (ANCOVA) model. It is defined as anti-log of the estimate of dependent variable minus 1, i.e., (exp\[ln(CRP at day 4/Baseline CRP)\]-1. Negative numbers imply improvement in CRP.

Time frame:
Baseline and Day 4
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline in CRP Levels at Day 4 in Participants With Serum IL-6 Level Greater Than the ULN (Phase 2)
Percent ChangePhase 2: PlaceboPhase 2: Sarilumab 200mg IVPhase 2: Sarilumab 400mg IV
Percent Change From Baseline in CRP Levels at Day 4 in Participants With Serum IL-6 Level Greater Than the ULN (Phase 2)-0.20 ± 0.077-0.77 ± 0.018-0.78 ± 0.017
Statistical analysis
  • Phase 2: Placebo vs Phase 2: Sarilumab 200mg IV · ANCOVA · p = <0.0001 (P-value is based on the ANCOVA model for differences between treatment groups in terms of \[ln(CRP at day 4 ) - ln(baseline CRP)\].) · Ls mean (log scale): -1.25 · 95% CI -1.456 to -1.035
  • Phase 2: Placebo vs Phase 2: Sarilumab 400mg IV · ANCOVA · p = <0.0001 (p-value is based on the ANCOVA model for differences between treatment groups in terms of \[ln(CRP at day 4 ) - ln(baseline CRP)\].) · Ls mean (log scale): -1.30 · 95% CI -1.511 to -1.090
PrimaryPercentage of Participants With at Least a 1-point Improvement in Clinical Status From Baseline to Day 22 Using the 7-point Ordinal Scale in Participants With Critical COVID-19 Receiving Mechanical Ventilation at Baseline (Phase 3 Cohort 1)

The ordinal scale is an assessment of the clinical status of a participant. The 7-point ordinal scale is as follows: 1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity

Time frame:
Day 22
Reported as:
Number · Percentage of participants
Percentage of Participants With at Least a 1-point Improvement in Clinical Status From Baseline to Day 22 Using the 7-point Ordinal Scale in Participants With Critical COVID-19 Receiving Mechanical Ventilation at Baseline (Phase 3 Cohort 1)
Percentage of participantsPhase 3 Cohort 1: Placebo - CriticalPhase 3 Cohort 1: Sarilumab 200mg IV - CriticalPhase 3 Cohort 1: Sarilumab 400mg IV - Critical
Percentage of Participants With at Least a 1-point Improvement in Clinical Status From Baseline to Day 22 Using the 7-point Ordinal Scale in Participants With Critical COVID-19 Receiving Mechanical Ventilation at Baseline (Phase 3 Cohort 1)35.5 (23.6 to 47.4)43.3 (33.7 to 52.8)43.2 (34.7 to 51.6)
Statistical analysis
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 200mg IV - Critical · Cochran-Mantel-Haenszel · p = 0.3707 (P-value based on stratified Cochran-Mantel-Haenszel test using the strata Use of Steroids at Baseline.) · Risk difference (rd): 7.1 · 95% CI -8.4 to 21.7
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 400mg IV - Critical · Cochran-Mantel-Haenszel · p = 0.3261 (P-value based on stratified Cochran-Mantel-Haenszel test using the strata Use of Steroids at Baseline.) · Risk difference (rd): 7.5 · 95% CI -7.4 to 21.3
PrimaryPercentage of Participants With at Least 1-point Improvement in Clinical Status Using the 7-point Ordinal Scale in Participants With COVID-19 Receiving Mechanical Ventilation at Baseline (Phase 3 Cohort 2)

The ordinal scale is an assessment of the clinical status of a participant The 7-point ordinal scale is as follows: 1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity

Time frame:
Day 22
Reported as:
Number · Percentage of participants
Percentage of Participants With at Least 1-point Improvement in Clinical Status Using the 7-point Ordinal Scale in Participants With COVID-19 Receiving Mechanical Ventilation at Baseline (Phase 3 Cohort 2)
Percentage of participantsPhase 3 Cohort 2: PlaceboPhase 3 Cohort 2: Sarilumab 800mg IV
Percentage of Participants With at Least 1-point Improvement in Clinical Status Using the 7-point Ordinal Scale in Participants With COVID-19 Receiving Mechanical Ventilation at Baseline (Phase 3 Cohort 2)60.0 (35.2 to 84.8)68.8 (46.0 to 91.5)
Statistical analysis
  • Phase 3 Cohort 2: Placebo vs Phase 3 Cohort 2: Sarilumab 800mg IV · Cochran-Mantel-Haenszel · p = 0.7328 · Risk difference (rd): 6.2 · 95% CI -26.2 to 36.8P-value based on stratified Cochran-Mantel-Haenszel test using the strata Use of Steroids at Baseline
SecondaryTime to Improvement (2 Points) in Clinical Status Assessment in Severe or Critical Patients With Serum IL-6 Levels Greater Than the Upper Limit of Normal (Phase 2)

Time to improvement (2 points) in clinical status assessment on the 7-point ordinal scale in severe or critical participants with serum IL-6 levels greater than the upper limit of normal (ULN). The ordinal scale is an assessment of the clinical status of a patient. The 7-point ordinal scale is as follows: 1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity

Time frame:
Up to Day 29
Reported as:
Median · Days
Time to Improvement (2 Points) in Clinical Status Assessment in Severe or Critical Patients With Serum IL-6 Levels Greater Than the Upper Limit of Normal (Phase 2)
DaysPhase 2: PlaceboPhase 2: Sarilumab 200mg IVPhase 2: Sarilumab 400mg IV
Time to Improvement (2 Points) in Clinical Status Assessment in Severe or Critical Patients With Serum IL-6 Levels Greater Than the Upper Limit of Normal (Phase 2)16.0 (11.0 to NA)15.0 (12.0 to 21.0)14.0 (10.0 to 21.0)
Statistical analysis
  • Phase 2: Placebo vs Phase 2: Sarilumab 200mg IV · Log Rank · p = 0.5687 (P-value based on log-rank test stratified by disease severity (severe, critical) and use of systemic corticosteroids for COVID-19 (Yes, No).) · Hazard ratio (hr): 1.12 · 95% CI 0.76 to 1.66
  • Phase 2: Placebo vs Phase 2: Sarilumab 400mg IV · Log Rank · p = 0.7014 (P-value based on log-rank test stratified by disease severity (severe, critical) and use of systemic corticosteroids for COVID-19 (Yes, No).) · Hazard ratio (hr): 1.09 · 95% CI 0.74 to 1.62
SecondaryTime to Improvement (2 Points) in Clinical Status Assessment in Severe or Critical Patients With All Serum IL-6 Levels (Phase 2)

Time to improvement (2 points) in clinical status assessment on the 7-point ordinal scale in severe or critical participants with all serum IL-6 levels. The 7-point ordinal scale is as follows: 1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity

Time frame:
Up to Day 29
Reported as:
Median · Days
Time to Improvement (2 Points) in Clinical Status Assessment in Severe or Critical Patients With All Serum IL-6 Levels (Phase 2)
DaysPhase 2: PlaceboPhase 2: Sarilumab 200mg IVPhase 2: Sarilumab 400mg IV
Time to Improvement (2 Points) in Clinical Status Assessment in Severe or Critical Patients With All Serum IL-6 Levels (Phase 2)15.0 (10.0 to 28.0)14.0 (11.0 to 19.0)13.0 (10.0 to 18.0)
Statistical analysis
  • Phase 2: Placebo vs Phase 2: Sarilumab 200mg IV · Log Rank · p = 0.3622 (P-value based on log-rank test stratified by disease severity (severe, critical) and use of systemic corticosteroids for COVID-19 (Yes, No).) · Hazard ratio (hr): 1.18 · 95% CI 0.83 to 1.70
  • Phase 2: Placebo vs Phase 2: Sarilumab 400mg IV · Log Rank · p = 0.5802 (P-value based on log-rank test stratified by disease severity (severe, critical) and use of systemic corticosteroids for COVID-19 (Yes, No).) · Hazard ratio (hr): 1.13 · 95% CI 0.79 to 1.63
SecondaryTime to Resolution of Fever for at Least 48 Hours Without Antipyretics or Until Discharge, Whichever is Sooner, in Patients With Documented Fever at Baseline (Phase 2)

Time to resolution of fever for at least 48 hours without antipyretics or until discharge, whichever is sooner, in patients with documented fever ≥38°C (oral), ≥38.4°C (rectal or tympanic), or ≥37.6°C (temporal or axillary) at Baseline. Resolution of fever is defined as postbaseline body temperature \<37.2°C (oral), or \<37.6°C (rectal or tympanic) or \<36.8°C (temporal or axillary).

Time frame:
Up to Day 29
Reported as:
Median · Days
Time to Resolution of Fever for at Least 48 Hours Without Antipyretics or Until Discharge, Whichever is Sooner, in Patients With Documented Fever at Baseline (Phase 2)
DaysPhase 2: PlaceboPhase 2: Sarilumab 200mg IVPhase 2: Sarilumab 400mg IV
Time to Resolution of Fever for at Least 48 Hours Without Antipyretics or Until Discharge, Whichever is Sooner, in Patients With Documented Fever at Baseline (Phase 2)17.0 (11.0 to NA)18.0 (11.0 to NA)18.0 (11.0 to NA)
Statistical analysis
  • Phase 2: Placebo vs Phase 2: Sarilumab 200mg IV · Log Rank · p = 0.2340 (P-value based on log-rank test stratified by disease severity (severe, critical and MSOD) and use of systemic corticosteroids for COVID-19 (Yes, No).) · Hazard ratio (hr): 1.29 · 95% CI 0.83 to 2.02
  • Phase 2: Placebo vs Phase 2: Sarilumab 400mg IV · Log Rank · p = 0.6949 (P-value based on log-rank test stratified by disease severity (severe, critical and MSOD) and use of systemic corticosteroids for COVID-19 (Yes, No).) · Hazard ratio (hr): 1.15 · 95% CI 0.74 to 1.79
SecondaryTime to Resolution of Fever for at Least 48 Hours Without Antipyretics by Clinical Severity (Phase 2)

Resolution of fever is defined as body temperature \<=36.8 C (axilla or temporal) or\<= 37.2 C (oral) or \<37.6 C (rectal or tympanic) for at least 48 hours without antipyretics or until discharge. Resolution of fever is defined only in participants with presence of fever at baseline.

Time frame:
Up to day 29
Reported as:
Median · Days
Time to Resolution of Fever for at Least 48 Hours Without Antipyretics by Clinical Severity (Phase 2)
DaysPhase 2: PlaceboPhase 2: Sarilumab 200mg IVPhase 2: Sarilumab 400mg IV
Disease Severity: Severe7.0 (4.0 to 10.0)5.0 (3.0 to 8.0)6.0 (5.0 to 11.0)
Disease Severity: CriticalNA (15.0 to NA)29.0 (16.0 to NA)20.5 (11.0 to NA)
Disease Severity: Multisystem Organ DysfunctionNA (11.0 to NA)NA (17.0 to NA)NA (18.0 to NA)
Statistical analysis
  • Phase 2: Placebo vs Phase 2: Sarilumab 200mg IV · Log Rank · p = 0.3151 (P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).) · Hazard ratio (hr): 1.27 · 95% CI 0.66 to 2.43
  • Phase 2: Placebo vs Phase 2: Sarilumab 400mg IV · Log Rank · p = 0.1884 (P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).) · Hazard ratio (hr): 0.74 · 95% CI 0.39 to 1.41
  • Phase 2: Placebo vs Phase 2: Sarilumab 200mg IV · Log Rank · p = 0.4356 (P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).) · Hazard ratio (hr): 1.61 · 95% CI 0.76 to 3.40
  • Phase 2: Placebo vs Phase 2: Sarilumab 400mg IV · Log Rank · p = 0.0371 (P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).) · Hazard ratio (hr): 2.10 · 95% CI 1.01 to 4.40
  • Phase 2: Placebo vs Phase 2: Sarilumab 200mg IV · Log Rank · p = 0.8923 (P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).) · Hazard ratio (hr): 0.98 · 95% CI 0.32 to 3.05
  • Phase 2: Placebo vs Phase 2: Sarilumab 400mg IV · Log Rank · p = 0.6940 (P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).) · Hazard ratio (hr): 0.83 · 95% CI 0.25 to 2.71
SecondaryTime to Resolution of Fever for at Least 48 Hours Without Antipyretics or Until Discharge, Whichever is Sooner, by Baseline IL-6 Levels (Phase 2)

Resolution of fever is defined as body temperature \<=36.8 C (axilla or temporal) or\<= 37.2 C (oral) or \<37.6 C (rectal or tympanic) for at least 48 hours without antipyretics or until discharge, by baseline IL-6 levels. Resolution of fever is defined only in participants with presence of fever at baseline.

Time frame:
Up to Day 29
Reported as:
Median · Days
Time to Resolution of Fever for at Least 48 Hours Without Antipyretics or Until Discharge, Whichever is Sooner, by Baseline IL-6 Levels (Phase 2)
DaysPhase 2: PlaceboPhase 2: Sarilumab 200mg IVPhase 2: Sarilumab 400mg IV
Disease Severity: Severe Baseline IL-6 < 87.04 picograms per milliliter (pg/mL) Median8.5 (4.0 to 12.0)5.0 (3.0 to 7.0)5.0 (3.0 to 6.0)
Disease Severity: Severe Baseline IL-6 >= 87.04pg/mL (Median)5.0 (3.0 to 8.0)8.0 (3.0 to 12.0)NA (4.0 to NA)
Disease Severity: Critical Baseline IL-6 < 166.68pg/mL (Median)14.0 (2.0 to NA)16.5 (5.0 to NA)17.0 (5.0 to NA)
Disease Severity: Critical Baseline IL-6 >= 166.68pg/mL (Median)NA (NA to NA)NA (16.0 to NA)25.0 (12.0 to NA)
Disease Severity: MSOD Baseline IL-6 <254.95 pg/mL (Median)NA (14.0 to NA)NA (9.0 to NA)NA (15.0 to NA)
Disease Severity: MSOD Baseline IL-6 >= 254.95 pg/mL (Median)NA (11.0 to NA)NA (2.0 to NA)NA (5.0 to NA)
Statistical analysis
  • Phase 2: Placebo vs Phase 2: Sarilumab 200mg IV · Log Rank · p = 0.0832 (P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).) · Hazard ratio (hr): 2.14 · 95% CI 0.81 to 5.65
  • Phase 2: Placebo vs Phase 2: Sarilumab 400mg IV · Log Rank · p = 0.1369 (P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).) · Hazard ratio (hr): 1.93 · 95% CI 0.77 to 4.80
  • Phase 2: Placebo vs Phase 2: Sarilumab 200mg IV · Log Rank · p = 0.9636 (P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).) · Hazard ratio (hr): 0.74 · 95% CI 0.28 to 1.95
  • Phase 2: Placebo vs Phase 2: Sarilumab 400mg IV · Log Rank · p = 0.0038 (P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).) · Hazard ratio (hr): 0.24 · 95% CI 0.08 to 0.74
  • Phase 2: Placebo vs Phase 2: Sarilumab 200mg IV · Log Rank · p = 0.7380 (P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).) · Hazard ratio (hr): 1.21 · 95% CI 0.47 to 3.13
  • Phase 2: Placebo vs Phase 2: Sarilumab 400mg IV · Log Rank · p = 0.7342 (P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).) · Hazard ratio (hr): 1.21 · 95% CI 0.48 to 3.05
  • Phase 2: Placebo vs Phase 2: Sarilumab 200mg IV · Log Rank · p = 0.1934 (P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).) · Hazard ratio (hr): 3.58 · 95% CI 0.79 to 16.17
  • Phase 2: Placebo vs Phase 2: Sarilumab 400mg IV · Log Rank · p = 0.0159 (P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).) · Hazard ratio (hr): 5.33 · 95% CI 1.19 to 23.94
  • Phase 2: Placebo vs Phase 2: Sarilumab 200mg IV · Log Rank · p = 0.6281 (P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).) · Hazard ratio (hr): 1.05 · 95% CI 0.13 to 8.75
  • Phase 2: Placebo vs Phase 2: Sarilumab 400mg IV · Log Rank · p = 0.4971 (P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).) · Hazard ratio (hr): 0.62 · 95% CI 0.06 to 6.13
  • Phase 2: Placebo vs Phase 2: Sarilumab 200mg IV · Log Rank · p = 0.2990 (P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).) · Hazard ratio (hr): 0.30 · 95% CI 0.03 to 2.86
  • Phase 2: Placebo vs Phase 2: Sarilumab 400mg IV · Log Rank · p = 0.9360 (P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).) · Hazard ratio (hr): 0.99 · 95% CI 0.22 to 4.41
SecondaryTime to Improvement in Oxygenation for at Least 48 Hours (Phase 2)

Improvement in oxygenation defined as increase in SpO2/FiO2 of 50 or greater compared to the nadir SpO2/FiO2

Time frame:
Up to day 29
Reported as:
Median · Days
Time to Improvement in Oxygenation for at Least 48 Hours (Phase 2)
DaysPhase 2: PlaceboPhase 2: Sarilumab 200mg IVPhase 2: Sarilumab 400mg IV
Disease Severity: Severe7.0 (5.0 to 9.0)6.0 (5.0 to 9.0)11.0 (6.0 to NA)
Disease Severity: Critical10.5 (7.0 to NA)20.0 (12.0 to NA)11.0 (8.0 to 15.0)
Disease Severity: MSOD20.0 (9.0 to NA)NA (12.0 to NA)19.0 (10.0 to NA)
Statistical analysis
  • Phase 2: Placebo vs Phase 2: Sarilumab 200mg IV · Log Rank · p = 0.9032 (P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).) · Hazard ratio (hr): 0.87 · 95% CI 0.52 to 1.47
  • Phase 2: Placebo vs Phase 2: Sarilumab 400mg IV · Log Rank · p = 0.0052 (P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).) · Hazard ratio (hr): 0.50 · 95% CI 0.29 to 0.88
  • Phase 2: Placebo vs Phase 2: Sarilumab 200mg IV · Log Rank · p = 0.1168 (P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).) · Hazard ratio (hr): 0.76 · 95% CI 0.48 to 1.21
  • Phase 2: Placebo vs Phase 2: Sarilumab 400mg IV · Log Rank · p = 0.3753 (P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).) · Hazard ratio (hr): 1.09 · 95% CI 0.69 to 1.72
  • Phase 2: Placebo vs Phase 2: Sarilumab 200mg IV · Log Rank · p = 0.4956 (P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).) · Hazard ratio (hr): 0.81 · 95% CI 0.40 to 1.66
  • Phase 2: Placebo vs Phase 2: Sarilumab 400mg IV · Log Rank · p = 0.8439 (P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).) · Cox proportional hazard: 1.01 · 95% CI 0.50 to 2.02
SecondaryTime to Improvement in Oxygenation for at Least 48 Hours by Baseline IL-6 Levels (Phase 2)

Time to Improvement defined as increase in SpO2/FiO2 of 50 or greater compared to the nadir SpO2/FiO2

Time frame:
Up to day 29
Reported as:
Median · Days
Time to Improvement in Oxygenation for at Least 48 Hours by Baseline IL-6 Levels (Phase 2)
DaysPhase 2: PlaceboPhase 2: Sarilumab 200mg IVPhase 2: Sarilumab 400mg IV
Severe Participants Baseline IL-6 < 67.11pg/mL (median)8.0 (2.0 to 12.0)5.0 (4.0 to 7.0)7.5 (4.0 to NA)
Severe Participants Baseline IL-6 >= 67.11pg/mL (median)6.5 (4.0 to 9.0)8.5 (5.0 to 11.0)NA (11.0 to NA)
Critical Participants Baseline IL-6 < 131.90pg/mL (median)7.0 (6.0 to NA)17.0 (8.0 to NA)8.5 (7.0 to 15.0)
Critical Participants Baseline IL-6 >= 131.90pg/mL (median)15.0 (6.0 to NA)NA (12.0 to NA)14.0 (8.0 to NA)
MSOD / Immunocompromised Participants Baseline IL-6 < 254.95pg/mL (median)14.0 (3.0 to NA)NA (7.0 to NA)24.0 (7.0 to NA)
MSOD / Immunocompromised Participants Baseline IL-6 >= 254.95pg/mL (median)24.0 (9.0 to NA)NA (8.0 to NA)19.0 (13.0 to NA)
Statistical analysis
  • Phase 2: Placebo vs Phase 2: Sarilumab 200mg IV · Log Rank · p = 0.3890 (P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).) · Hazard ratio (hr): 1.21 · 95% CI 0.52 to 2.79
  • Phase 2: Placebo vs Phase 2: Sarilumab 200mg IV · Log Rank · p = 0.7838 (P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).) · Hazard ratio (hr): 0.65 · 95% CI 0.30 to 1.41
  • Phase 2: Placebo vs Phase 2: Sarilumab 400mg IV · Log Rank · p = 0.2370 (P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).) · Hazard ratio (hr): 0.68 · 95% CI 0.28 to 1.65
  • Phase 2: Placebo vs Phase 2: Sarilumab 400mg IV · Log Rank · p = 0.0004 (P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).) · Hazard ratio (hr): 0.25 · 95% CI 0.10 to 0.59
  • Phase 2: Placebo vs Phase 2: Sarilumab 200mg IV · Log Rank · p = 0.1740 (P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).) · Hazard ratio (hr): 0.70 · 95% CI 0.37 to 1.32
  • Phase 2: Placebo vs Phase 2: Sarilumab 200mg IV · Log Rank · p = 0.3664 (P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).) · Hazard ratio (hr): 0.80 · 95% CI 0.38 to 1.66
  • Phase 2: Placebo vs Phase 2: Sarilumab 400mg IV · Log Rank · p = 0.7318 (P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).) · Hazard ratio (hr): 1.00 · 95% CI 0.53 to 1.87
  • Phase 2: Placebo vs Phase 2: Sarilumab 400mg IV · Log Rank · p = 0.4155 (P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).) · Hazard ratio (hr): 1.18 · 95% CI 0.59 to 2.37
  • Phase 2: Placebo vs Phase 2: Sarilumab 200mg IV · Log Rank · p = 0.6262 (P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).) · Hazard ratio (hr): 0.75 · 95% CI 0.23 to 2.45
  • Phase 2: Placebo vs Phase 2: Sarilumab 200mg IV · Log Rank · p = 0.5530 (P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).) · Hazard ratio (hr): 0.70 · 95% CI 0.21 to 2.30
  • Phase 2: Placebo vs Phase 2: Sarilumab 400mg IV · Log Rank · p = 0.8775 (P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).) · Hazard ratio (hr): 0.85 · 95% CI 0.25 to 2.85
  • Phase 2: Placebo vs Phase 2: Sarilumab 400mg IV · Log Rank · p = 0.7485 (P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).) · Hazard ratio (hr): 1.10 · 95% CI 0.41 to 2.99
SecondaryTime to Resolution of Fever and Improvement in Oxygenation for at Least 48 Hours (Phase 2)

Resolution of fever defined as postbaseline body temperature \<37.2°C (oral), or \<37.6°C (rectal or tympanic) or \<36.8°C (temporal or axillary) Improvement in oxygenation defined as increase in SpO2/FiO2 of 50 or greater compared to the nadir SpO2/FiO2

Time frame:
Up to day 29
Reported as:
Median · Days
Time to Resolution of Fever and Improvement in Oxygenation for at Least 48 Hours (Phase 2)
DaysPhase 2: PlaceboPhase 2: Sarilumab 200mg IVPhase 2: Sarilumab 400mg IV
Disease Severity: Severe7.0 (4.0 to 7.0)4.0 (3.0 to 8.0)6.0 (4.0 to NA)
Disease Severity: Critical15.0 (7.0 to NA)22.0 (8.0 to NA)8.5 (7.0 to 14.0)
Disease Severity: MSOD20.0 (8.0 to NA)NA (9.0 to NA)24.0 (9.0 to NA)
Statistical analysis
  • Phase 2: Placebo vs Phase 2: Sarilumab 200mg IV · Log Rank · p = 0.4556 (P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).) · Hazard ratio (hr): 1.06 · 95% CI 0.63 to 1.79
  • Phase 2: Placebo vs Phase 2: Sarilumab 400mg IV · Log Rank · p = 0.0248 (P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).) · Hazard ratio (hr): 0.60 · 95% CI 0.35 to 1.04
  • Phase 2: Placebo vs Phase 2: Sarilumab 200mg IV · Log Rank · p = 0.6842 (P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).) · Hazard ratio (hr): 1.02 · 95% CI 0.62 to 1.67
  • Phase 2: Placebo vs Phase 2: Sarilumab 400mg IV · Log Rank · p = 0.0671 (P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).) · Hazard ratio (hr): 1.43 · 95% CI 0.89 to 2.32
  • Phase 2: Placebo vs Phase 2: Sarilumab 200mg IV · Log Rank · p = 0.6146 (P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).) · Hazard ratio (hr): 0.85 · 95% CI 0.41 to 1.74
  • Phase 2: Placebo vs Phase 2: Sarilumab 400mg IV · Log Rank · p = 0.9730 (P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).) · Hazard ratio (hr): 0.98 · 95% CI 0.48 to 1.99
SecondaryPercentage of Participants in Each Clinical Status Category Using the 7-point Ordinal Scale up to Day 29 (Phase 2)

Percentage of participants in each clinical status category using the 7-point ordinal scale from Baseline (Day 1) up to Day 29. The 7-point ordinal scale is as follows: 1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity

Time frame:
Days 1, 3, 5, 8, 11, 15 and 29
Reported as:
Number · Percentage of Participants
Percentage of Participants in Each Clinical Status Category Using the 7-point Ordinal Scale up to Day 29 (Phase 2)
Percentage of ParticipantsPhase 2: PlaceboPhase 2: Sarilumab 200mg IVPhase 2: Sarilumab 400mg IV
Disease Severity: Severe Day 1 Ordinal Scale = 1000
Disease Severity: Severe Day 1 Ordinal Scale = 2007.8
Disease Severity: Severe Day 1 Ordinal Scale = 302.03.9
Disease Severity: Severe Day 1 Ordinal Scale = 410094.088.2
Disease Severity: Severe Day 1 Ordinal Scale = 504.00
Disease Severity: Severe Day 1 Ordinal Scale = 6000
Disease Severity: Severe Day 1 Ordinal Scale = 7000
Disease Severity: Severe Day 3 Ordinal Scale = 1000
Disease Severity: Severe Day 3 Ordinal Scale = 204.013.7
Disease Severity: Severe Day 3 Ordinal Scale = 34.06.05.9
Disease Severity: Severe Day 3 Ordinal Scale = 496.088.072.5
Disease Severity: Severe Day 3 Ordinal Scale = 502.03.9
Disease Severity: Severe Day 3 Ordinal Scale = 6000
Disease Severity: Severe Day 3 Ordinal Scale = 7003.9
Disease Severity: Severe Day 5 Ordinal Scale = 1000
Disease Severity: Severe Day 5 Ordinal Scale = 28.06.021.6
Disease Severity: Severe Day 5 Ordinal Scale = 308.03.9
Disease Severity: Severe Day 5 Ordinal Scale = 472.066.049.0
Disease Severity: Severe Day 5 Ordinal Scale = 504.011.8
Disease Severity: Severe Day 5 Ordinal Scale = 64.02.02.0
Disease Severity: Severe Day 5 Ordinal Scale = 716.014.011.8
Disease Severity: Severe Day 8 Ordinal Scale = 102.00
Disease Severity: Severe Day 8 Ordinal Scale = 28.04.019.6
Disease Severity: Severe Day 8 Ordinal Scale = 34.08.05.9
Disease Severity: Severe Day 8 Ordinal Scale = 448.034.029.4
Disease Severity: Severe Day 8 Ordinal Scale = 506.02.0
Disease Severity: Severe Day 8 Ordinal Scale = 6000
Disease Severity: Severe Day 8 Ordinal Scale = 740.046.043.1
Disease Severity: Severe Day 11 Ordinal Scale = 102.011.8
Disease Severity: Severe Day 11 Ordinal Scale = 28.04.011.8
Disease Severity: Severe Day 11 Ordinal Scale = 306.03.9
Disease Severity: Severe Day 11 Ordinal Scale = 432.014.09.8
Disease Severity: Severe Day 11 Ordinal Scale = 54.002.0
Disease Severity: Severe Day 11 Ordinal Scale = 6000
Disease Severity: Severe Day 11 Ordinal Scale = 756.074.060.8
Disease Severity: Severe Day 15 Ordinal Scale = 104.015.7
Disease Severity: Severe Day 15 Ordinal Scale = 24.02.09.8
Disease Severity: Severe Day 15 Ordinal Scale = 302.00
Disease Severity: Severe Day 15 Ordinal Scale = 416.06.05.9
Disease Severity: Severe Day 15 Ordinal Scale = 54.000
Disease Severity: Severe Day 15 Ordinal Scale = 6000
Disease Severity: Severe Day 15 Ordinal Scale = 776.086.068.6
Disease Severity: Severe Day 29 Ordinal Scale = 104.017.6
Disease Severity: Severe Day 29 Ordinal Scale = 202.07.8
Disease Severity: Severe Day 29 Ordinal Scale = 3002.0
Disease Severity: Severe Day 29 Ordinal Scale = 48.02.02.0
Disease Severity: Severe Day 29 Ordinal Scale = 5000
Disease Severity: Severe Day 29 Ordinal Scale = 6000
Disease Severity: Severe Day 29 Ordinal Scale = 792.092.070.6
Disease Severity: Critical Day 1 Ordinal Scale = 1000
Disease Severity: Critical Day 1 Ordinal Scale = 240.964.954.5
Disease Severity: Critical Day 1 Ordinal Scale = 39.16.46.8
Disease Severity: Critical Day 1 Ordinal Scale = 450.028.738.6
Disease Severity: Critical Day 1 Ordinal Scale = 5000
Disease Severity: Critical Day 1 Ordinal Scale = 6000
Disease Severity: Critical Day 1 Ordinal Scale = 7000
Disease Severity: Critical Day 3 Ordinal Scale = 103.21.1
Disease Severity: Critical Day 3 Ordinal Scale = 259.171.356.8
Disease Severity: Critical Day 3 Ordinal Scale = 39.16.410.2
Disease Severity: Critical Day 3 Ordinal Scale = 431.819.128.4
Disease Severity: Critical Day 3 Ordinal Scale = 5001.1
Disease Severity: Critical Day 3 Ordinal Scale = 6000
Disease Severity: Critical Day 3 Ordinal Scale = 7001.1
Disease Severity: Critical Day 3 Ordinal Scale = Missing4.800
Disease Severity: Critical Day 5 Ordinal Scale = 109.64.5
Disease Severity: Critical Day 5 Ordinal Scale = 252.364.953.4
Disease Severity: Critical Day 5 Ordinal Scale = 311.48.59.1
Disease Severity: Critical Day 5 Ordinal Scale = 434.114.928.4
Disease Severity: Critical Day 5 Ordinal Scale = 52.302.3
Disease Severity: Critical Day 5 Ordinal Scale = 6000
Disease Severity: Critical Day 5 Ordinal Scale = 702.12.3
Disease Severity: Critical Day 8 Ordinal Scale = 16.820.29.1
Disease Severity: Critical Day 8 Ordinal Scale = 243.250.046.6
Disease Severity: Critical Day 8 Ordinal Scale = 36.85.31.1
Disease Severity: Critical Day 8 Ordinal Scale = 429.516.027.3
Disease Severity: Critical Day 8 Ordinal Scale = 501.10
Disease Severity: Critical Day 8 Ordinal Scale = 6000
Disease Severity: Critical Day 8 Ordinal Scale = 713.67.415.9
Disease Severity: Critical Day 11 Ordinal Scale = 19.121.311.4
Disease Severity: Critical Day 11 Ordinal Scale = 245.541.537.5
Disease Severity: Critical Day 11 Ordinal Scale = 306.42.3
Disease Severity: Critical Day 11 Ordinal Scale = 420.511.719.3
Disease Severity: Critical Day 11 Ordinal Scale = 502.12.3
Disease Severity: Critical Day 11 Ordinal Scale = 6001.1
Disease Severity: Critical Day 11 Ordinal Scale = 725.017.026.1
Disease Severity: Critical Day 15 Ordinal Scale = 118.227.713.6
Disease Severity: Critical Day 15 Ordinal Scale = 236.424.529.5
Disease Severity: Critical Day 15 Ordinal Scale = 303.21.1
Disease Severity: Critical Day 15 Ordinal Scale = 413.619.114.8
Disease Severity: Critical Day 15 Ordinal Scale = 503.21.1
Disease Severity: Critical Day 15 Ordinal Scale = 601.11.1
Disease Severity: Critical Day 15 Ordinal Scale = 731.821.338.6
Disease Severity: Critical Day 29 Ordinal Scale = 127.337.225.0
Disease Severity: Critical Day 29 Ordinal Scale = 227.37.45.7
Disease Severity: Critical Day 29 Ordinal Scale = 302.10
Disease Severity: Critical Day 29 Ordinal Scale = 44.54.39.1
Disease Severity: Critical Day 29 Ordinal Scale = 502.13.4
Disease Severity: Critical Day 29 Ordinal Scale = 6000
Disease Severity: Critical Day 29 Ordinal Scale = 740.946.856.8
Disease Severity: MSOD Day 1 Ordinal Scale = 1000
Disease Severity: MSOD Day 1 Ordinal Scale = 2100100100
Disease Severity: MSOD Day 1 Ordinal Scale = 3000
Disease Severity: MSOD Day 1 Ordinal Scale = 4000
Disease Severity: MSOD Day 1 Ordinal Scale = 5000
Disease Severity: MSOD Day 1 Ordinal Scale = 6000
Disease Severity: MSOD Day 1 Ordinal Scale = 7000
Disease Severity: MSOD Day 3 Ordinal Scale = 104.72.4
Disease Severity: MSOD Day 3 Ordinal Scale = 210095.397.6
Disease Severity: MSOD Day 3 Ordinal Scale = 3000
Disease Severity: MSOD Day 3 Ordinal Scale = 4000
Disease Severity: MSOD Day 3 Ordinal Scale = 5000
Disease Severity: MSOD Day 3 Ordinal Scale = 6000
Disease Severity: MSOD Day 3 Ordinal Scale = 7000
Disease Severity: MSOD Day 5 Ordinal Scale = 19.59.314.6
Disease Severity: MSOD Day 5 Ordinal Scale = 290.588.482.9
Disease Severity: MSOD Day 5 Ordinal Scale = 3000
Disease Severity: MSOD Day 5 Ordinal Scale = 402.32.4
Disease Severity: MSOD Day 5 Ordinal Scale = 5000
Disease Severity: MSOD Day 5 Ordinal Scale = 6000
Disease Severity: MSOD Day 5 Ordinal Scale = 7000
Disease Severity: MSOD Day 8 Ordinal Scale = 119.014.019.5
Disease Severity: MSOD Day 8 Ordinal Scale = 271.469.875.6
Disease Severity: MSOD Day 8 Ordinal Scale = 39.500
Disease Severity: MSOD Day 8 Ordinal Scale = 4014.04.9
Disease Severity: MSOD Day 8 Ordinal Scale = 502.30
Disease Severity: MSOD Day 8 Ordinal Scale = 6000
Disease Severity: MSOD Day 8 Ordinal Scale = 7000
Disease Severity: MSOD Day 11 Ordinal Scale = 119.025.626.8
Disease Severity: MSOD Day 11 Ordinal Scale = 266.746.561.0
Disease Severity: MSOD Day 11 Ordinal Scale = 34.84.70
Disease Severity: MSOD Day 11 Ordinal Scale = 49.511.67.3
Disease Severity: MSOD Day 11 Ordinal Scale = 504.70
Disease Severity: MSOD Day 11 Ordinal Scale = 602.32.4
Disease Severity: MSOD Day 11 Ordinal Scale = 704.72.4
Disease Severity: MSOD Day 15 Ordinal Scale = 123.834.931.7
Disease Severity: MSOD Day 15 Ordinal Scale = 238.134.951.2
Disease Severity: MSOD Day 15 Ordinal Scale = 302.30
Disease Severity: MSOD Day 15 Ordinal Scale = 433.32.39.8
Disease Severity: MSOD Day 15 Ordinal Scale = 507.00
Disease Severity: MSOD Day 15 Ordinal Scale = 6000
Disease Severity: MSOD Day 15 Ordinal Scale = 74.818.67.3
Disease Severity: MSOD Day 29 Ordinal Scale = 133.341.939.0
Disease Severity: MSOD Day 29 Ordinal Scale = 219.014.014.6
Disease Severity: MSOD Day 29 Ordinal Scale = 302.34.9
Disease Severity: MSOD Day 29 Ordinal Scale = 49.52.39.8
Disease Severity: MSOD Day 29 Ordinal Scale = 507.09.8
Disease Severity: MSOD Day 29 Ordinal Scale = 604.70
Disease Severity: MSOD Day 29 Ordinal Scale = 733.327.922.0
Disease Severity: MSOD Day 29 Ordinal Scale = Missing001.1
SecondaryTime to Discharge or to a National Early Warning Score 2 (NEWS2) of ≤2 and Maintained for 24 Hours (Phase 2)

NEWS2 was used to standardize assessment of acute-illness severity, track clinical condition of participants and to alert clinical teams to participant deterioration. NEWS2 score was based on 7 clinical parameters: respiration rate, oxygen saturation, supplemental oxygen, systolic blood pressure, pulse rate, level of consciousness, and temperature. A score of 0, 1, 2, and 3 was allocated to each parameter except supplemental oxygen (a score of 0 or 1 was allocated) and level of consciousness (a score of 0 or 3 was allocated), where 0 = normal health condition to 3 = worst health condition; higher score indicated more severity. All scores were summed to get an aggregate score. Aggregate NEWS2 score ranged from 0 to 19, with higher scores meaning more severity/higher risk: low risk (score 0 to 4); low to medium risk (score of 3 in any individual parameter); medium risk (score 5 to 6); high risk (score 7 to 19).

Time frame:
Up to day 29
Reported as:
Median · Days
Time to Discharge or to a National Early Warning Score 2 (NEWS2) of ≤2 and Maintained for 24 Hours (Phase 2)
DaysPhase 2: PlaceboPhase 2: Sarilumab 200mg IVPhase 2: Sarilumab 400mg IV
Disease Severity: Severe6.0 (4.0 to 8.0)6.0 (4.0 to 7.0)6.0 (4.0 to 7.0)
Disease Severity: CriticalNA (9.0 to NA)25.0 (19.0 to NA)15.0 (10.0 to 20.0)
Disease Severity: MSODNA (18.0 to NA)NA (24.0 to NA)NA (23.0 to NA)
Statistical analysis
  • Phase 2: Placebo vs Phase 2: Sarilumab 200mg IV · Log Rank · p = 0.6987 (P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).) · Hazard ratio (hr): 0.97 · 95% CI 0.59 to 1.59
  • Phase 2: Placebo vs Phase 2: Sarilumab 400mg IV · Log Rank · p = 0.0453 (P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).) · Hazard ratio (hr): 0.65 · 95% CI 0.39 to 1.09
  • Phase 2: Placebo vs Phase 2: Sarilumab 200mg IV · Log Rank · p = 0.9734 (P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).) · Hazard ratio (hr): 1.23 · 95% CI 0.73 to 2.09
  • Phase 2: Placebo vs Phase 2: Sarilumab 400mg IV · Log Rank · p = 0.0040 (P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No)) · Hazard ratio (hr): 1.91 · 95% CI 1.14 to 3.20
  • Phase 2: Placebo vs Phase 2: Sarilumab 200mg IV · Log Rank · p = 0.9551 (P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).) · Hazard ratio (hr): 0.97 · 95% CI 0.43 to 2.17
  • Phase 2: Placebo vs Phase 2: Sarilumab 400mg IV · Log Rank · p = 0.8722 (P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).) · Hazard ratio (hr): 0.94 · 95% CI 0.42 to 2.10
SecondaryChange From Baseline in NEWS2 Scoring System (Phase 2)

NEWS2 was used to standardize assessment of acute-illness severity, track clinical condition of participants and to alert clinical teams to participant deterioration. NEWS2 score was based on 7 clinical parameters: respiration rate, oxygen saturation, supplemental oxygen, systolic blood pressure, pulse rate, level of consciousness, and temperature. A score of 0, 1, 2, and 3 was allocated to each parameter except supplemental oxygen (a score of 0 or 1 was allocated) and level of consciousness (a score of 0 or 3 was allocated), where 0 = normal health condition to 3 = worst health condition; higher score indicated more severity. All scores were summed to get an aggregate score. Aggregate NEWS2 score ranged from 0 to 19, with higher scores meaning more severity/higher risk: low risk (score 0 to 4); low to medium risk (score of 3 in any individual parameter); medium risk (score 5 to 6); high risk (score 7 to 19).

Time frame:
Days 3, 5, 8, 11, 15 and 29
Reported as:
Mean · scores on a scale
Change From Baseline in NEWS2 Scoring System (Phase 2)
scores on a scalePhase 2: PlaceboPhase 2: Sarilumab 200mg IVPhase 2: Sarilumab 400mg IV
Day 30.46 ± 2.290.14 ± 2.690.03 ± 3.00
Day 50.36 ± 3.180.00 ± 2.980.03 ± 3.26
Day 8-0.17 ± 3.05-0.22 ± 3.33-0.31 ± 3.65
Day 110.00 ± 3.53-0.27 ± 3.65-0.29 ± 4.29
Day 15-0.40 ± 3.55-0.45 ± 3.91-0.48 ± 4.50
Day 29-0.67 ± 4.12-1.12 ± 4.23-1.34 ± 4.75
SecondaryNumber of Days With Fever (Phase 2)

Defined as ≥38°C (oral), ≥38.4°C (rectal or tympanic) or ≥37.6°C (temporal or axillary)

Time frame:
Up to Day 29
Reported as:
Mean · Days
Number of Days With Fever (Phase 2)
DaysPhase 2: PlaceboPhase 2: Sarilumab 200mg IVPhase 2: Sarilumab 400mg IV
Number of Days With Fever (Phase 2)6.3 ± 5.924.2 ± 4.375.8 ± 7.49
SecondaryPercentage of Participants Alive, Off Oxygen (Phase 2)
Time frame:
At Day 29
Reported as:
Number · percentage of participants
Percentage of Participants Alive, Off Oxygen (Phase 2)
percentage of participantsPhase 2: PlaceboPhase 2: Sarilumab 200mg IVPhase 2: Sarilumab 400mg IV
Disease Severity: Severe92.0 (81.4 to 100.0)92.0 (84.5 to 99.5)70.6 (58.1 to 83.1)
Disease Severity: Critical40.9 (26.4 to 55.4)50.0 (39.9 to 60.1)61.4 (51.2 to 71.5)
Disease Severity: MSOD38.1 (17.3 to 58.9)39.5 (24.9 to 54.1)34.1 (19.6 to 48.7)
Statistical analysis
  • Phase 2: Placebo vs Phase 2: Sarilumab 200mg IV · Chi-squared · p = 1.0000
  • Phase 2: Placebo vs Phase 2: Sarilumab 400mg IV · Chi-squared · p = 0.0353
  • Phase 2: Placebo vs Phase 2: Sarilumab 200mg IV · Chi-squared · p = 0.3187
  • Phase 2: Placebo vs Phase 2: Sarilumab 400mg IV · Chi-squared · p = 0.0261
  • Phase 2: Placebo vs Phase 2: Sarilumab 200mg IV · Chi-squared · p = 0.9117
  • Phase 2: Placebo vs Phase 2: Sarilumab 400mg IV · Chi-squared · p = 0.7584
SecondaryNumber of Days of Resting Respiratory Rate >24 Breaths/Min (Phase 2)
Time frame:
Up to day 29
Reported as:
Mean · Days
Number of Days of Resting Respiratory Rate >24 Breaths/Min (Phase 2)
DaysPhase 2: PlaceboPhase 2: Sarilumab 200mg IVPhase 2: Sarilumab 400mg IV
Number of Days of Resting Respiratory Rate >24 Breaths/Min (Phase 2)9.2 ± 10.297.3 ± 8.218.2 ± 7.99
SecondaryNumber of Days With Hypoxemia (Phase 2)
Time frame:
Up to day 29
Reported as:
Mean · Days
Number of Days With Hypoxemia (Phase 2)
DaysPhase 2: PlaceboPhase 2: Sarilumab 200mg IVPhase 2: Sarilumab 400mg IV
Number of Days With Hypoxemia (Phase 2)18.1 ± 14.1614.5 ± 11.9616.4 ± 13.94
SecondaryNumber of Days of Supplemental Oxygen Use (Phase 2)
Time frame:
Up to day 29
Reported as:
Mean · days
Number of Days of Supplemental Oxygen Use (Phase 2)
daysPhase 2: PlaceboPhase 2: Sarilumab 200mg IVPhase 2: Sarilumab 400mg IV
Number of Days of Supplemental Oxygen Use (Phase 2)17.7 ± 14.1514.1 ± 11.9216.2 ± 14.02
SecondaryTime to Saturation ≥94% on Room Air (Phase 2)
Time frame:
Up to day 29
Reported as:
Median · Days
Time to Saturation ≥94% on Room Air (Phase 2)
DaysPhase 2: PlaceboPhase 2: Sarilumab 200mg IVPhase 2: Sarilumab 400mg IV
Disease Severity: SevereNA (6.0 to NA)NA (NA to NA)NA (NA to NA)
Disease Severity: CriticalNA (3.0 to NA)NA (5.0 to NA)NA (NA to NA)
Disease Severity: MSOD5.0 (2.0 to NA)NA (4.0 to NA)NA (4.0 to NA)
Statistical analysis
  • Phase 2: Placebo vs Phase 2: Sarilumab 200mg IV · Log Rank · p = 0.0385 (P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).) · Hazard ratio (hr): 0.32 · 95% CI 0.11 to 0.94
  • Phase 2: Placebo vs Phase 2: Sarilumab 400mg IV · Log Rank · p = 0.0782 (P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).) · Hazard ratio (hr): 0.38 · 95% CI 0.14 to 1.05
  • Phase 2: Placebo vs Phase 2: Sarilumab 200mg IV · Log Rank · p = 0.2436 (P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).) · Hazard ratio (hr): 1.22 · 95% CI 0.70 to 2.14
  • Phase 2: Placebo vs Phase 2: Sarilumab 400mg IV · Log Rank · p = 0.3223 (P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).) · Hazard ratio (hr): 0.83 · 95% CI 0.46 to 1.51
  • Phase 2: Placebo vs Phase 2: Sarilumab 200mg IV · Log Rank · p = 0.4670 (P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).) · Hazard ratio (hr): 0.74 · 95% CI 0.36 to 1.52
  • Phase 2: Placebo vs Phase 2: Sarilumab 400mg IV · Log Rank · p = 0.3728 (P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).) · Hazard ratio (hr): 0.71 · 95% CI 0.35 to 1.47
SecondaryNumber of Ventilator Free Days (Phase 2)

Summary of Ventilator-free days during study in Participants using Invasive Mechanical Ventilation at Baseline

Time frame:
Up to Day 22
Reported as:
Mean · Days
Number of Ventilator Free Days (Phase 2)
DaysPhase 2: PlaceboPhase 2: Sarilumab 200mg IVPhase 2: Sarilumab 400mg IV
Disease Severity: Severe19.9 ± 4.219.7 ± 4.715.5 ± 9.1
Disease Severity: Critical8.9 ± 9.67.6 ± 8.510.9 ± 9.3
Disease Severity: MSOD4.5 ± 5.54.6 ± 6.53.3 ± 5.1
SecondaryNumber of Participants Who Initiated Mechanical Ventilation After Baseline (Phase 2)
Time frame:
Up to Day 29
Reported as:
Count of participants · Participants
Number of Participants Who Initiated Mechanical Ventilation After Baseline (Phase 2)
ParticipantsPhase 2: PlaceboPhase 2: Sarilumab 200mg IVPhase 2: Sarilumab 400mg IV
Disease Severity: Severe249
Disease Severity: Critical131411
Disease Severity: MSOD000
SecondaryNumber of Days in an Intensive Care Unit (ICU) in Participants Who Were Not in ICU at Baseline (Phase 2)
Time frame:
Up to Day 29
Reported as:
Mean · Days
Number of Days in an Intensive Care Unit (ICU) in Participants Who Were Not in ICU at Baseline (Phase 2)
DaysPhase 2: PlaceboPhase 2: Sarilumab 200mg IVPhase 2: Sarilumab 400mg IV
Number of Days in an Intensive Care Unit (ICU) in Participants Who Were Not in ICU at Baseline (Phase 2)13.6 ± 11.011.4 ± 10.513.8 ± 15.5
SecondaryNumber of Days of Hospitalization Among Survivors (Phase 2)
Time frame:
Up to day 29
Reported as:
Mean · days
Number of Days of Hospitalization Among Survivors (Phase 2)
daysPhase 2: PlaceboPhase 2: Sarilumab 200mg IVPhase 2: Sarilumab 400mg IV
Up to Day 87.3 ± 1.37.3 ± 1.37.2 ± 1.5
Up to Day 1513.7 ± 2.013.5 ± 2.213.5 ± 2.2
Up to Day 2221.3 ± 1.821.2 ± 1.721.6 ± 1.1
Up to Day 2927.3 ± 2.527.5 ± 2.228.4 ± 1.4
SecondaryNumber of Deaths Due to Any Cause

Number of deaths due to any cause (All-Cause Mortality)

Time frame:
Up to day 60
Reported as:
Number · deaths
Number of Deaths Due to Any Cause
deathsPhase 2: PlaceboPhase 2: Sarilumab 200mg IVPhase 2: Sarilumab 400mg IVPhase 3 Cohort 1: Placebo - CriticalPhase 3 Cohort 1: 200mg IV - CriticalPhase 3 Cohort 1:Sarilumab 400mg IV - CriticalPhase 3 Cohort 1: Placebo - SeverePhase 3 Cohort 1: Sarilumab 200mg IV - SeverePhase 3 Cohort 1: Sarilumab 400mg IV - SeverePhase 3 Cohort 1: Placebo - MSODPhase 3 Cohort 1: Sarilumab 200mg IV - MSODPhase 3 Cohort 1: Sarilumab 400mg IV - MSODPhase 3 Cohort 1: Placebo - ImmunocompromisedPhase 3 Cohort 1: Sarilumab 200mg IV - ImmunocompromisedPhase 3 Cohort 1: Sarilumab 400mg IV - ImmunocompromisedPhase 3 Cohort 2: PlaceboPhase 3 Cohort 2: Sarilumab 800 mg IVPhase 3 Cohort 3: PlaceboPhase 3 Cohort 3: Sarilumab 800 mg IV
Number of Deaths Due to Any Cause2460495970114912211640403464310
SecondaryPercentage of Participants With at Least 1-point Improvement in Clinical Status Using the 7-point Ordinal Scale in Participants With Critical COVID-19 (Phase 3 Cohort 1: Critical ITT)

The ordinal scale is an assessment of the clinical status of a participant. The 7-point ordinal scale is as follows: 1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity

Time frame:
Day 22
Reported as:
Number · Percentage of Participants
Percentage of Participants With at Least 1-point Improvement in Clinical Status Using the 7-point Ordinal Scale in Participants With Critical COVID-19 (Phase 3 Cohort 1: Critical ITT)
Percentage of ParticipantsPhase 3 Cohort 1: Placebo - CriticalPhase 3 Cohort 1: Sarilumab 200mg IV - CriticalPhase 3 Cohort 1: Sarilumab 400mg IV - Critical
Percentage of Participants With at Least 1-point Improvement in Clinical Status Using the 7-point Ordinal Scale in Participants With Critical COVID-19 (Phase 3 Cohort 1: Critical ITT)54.1 (46.6 to 61.6)56.6 (50.4 to 62.9)51.5 (46.2 to 56.8)
Statistical analysis
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 200mg IV - Critical · Cochran-Mantel-Haenszel · p = 0.5851 (P-value based on stratified Cochran-Mantel-Haenszel test using the strata Use of Steroids at Baseline.) · Risk difference (rd): 2.7 · 95% CI -7.0 to 12.4
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 400mg IV - Critical · Cochran-Mantel-Haenszel · p = 0.5767 (P-value based on stratified Cochran-Mantel-Haenszel test using the strata Use of Steroids at Baseline.) · Risk difference (rd): -2.6 · 95% CI -11.7 to 6.5
SecondaryPercentage of Participants Who Recover (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)

Percentage of Participants Who Recover (Discharged, or Alive without Supplemental Oxygen Use or at Pre-COVID Oxygen Use) at Day 22

Time frame:
Day 22
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Recover (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)
Percentage of ParticipantsPhase 3 Cohort 1: Placebo - CriticalPhase 3 Cohort 1: Sarilumab 200mg IV - CriticalPhase 3 Cohort 1: Sarilumab 400mg IV - Critical
Percentage of Participants Who Recover (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)25.8 (14.9 to 36.7)30.8 (21.9 to 39.6)31.8 (23.9 to 39.8)
Statistical analysis
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 200mg IV - Critical · Cochran-Mantel-Haenszel · p = 0.4777 (P-value based on stratified Cochran-Mantel-Haenszel test using the strata Use of Steroids at Baseline.) · Risk difference (rd): 5.2 · 95% CI -9.4 to 18.6
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 400mg IV - Critical · Cochran-Mantel-Haenszel · p = 0.4202 (P-value based on stratified Cochran-Mantel-Haenszel test using the strata Use of Steroids at Baseline.) · Risk difference (rd): 5.7 · 95% CI -8.4 to 18.2
SecondaryPercentage of Participants Who Recover (Phase 3 Cohort 1: Critical ITT)

Percentage of Participants Who Recover (Discharged, or Alive without Supplemental Oxygen Use or at Pre-COVID Oxygen Use) at Day 22

Time frame:
Day 22
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Recover (Phase 3 Cohort 1: Critical ITT)
Percentage of ParticipantsPhase 3 Cohort 1: Placebo - CriticalPhase 3 Cohort 1: Sarilumab 200mg IV - CriticalPhase 3 Cohort 1: Sarilumab 400mg IV - Critical
Percentage of Participants Who Recover (Phase 3 Cohort 1: Critical ITT)50.0 (42.5 to 57.5)49.6 (43.3 to 55.9)45.3 (40.0 to 50.6)
Statistical analysis
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 200mg IV - Critical · Cochran-Mantel-Haenszel · p = 0.9696 (P-value based on stratified Cochran-Mantel-Haenszel test using the strata Use of Steroids at Baseline.) · Risk difference (rd): 0.2 · 95% CI -9.5 to 9.9
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 400mg IV - Critical · Cochran-Mantel-Haenszel · p = 0.3152 (P-value based on stratified Cochran-Mantel-Haenszel test using the strata Use of Steroids at Baseline.) · Risk difference (rd): -4.7 · 95% CI -13.8 to 4.4
SecondaryPercentage of Participants Who Die (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)

Percentage of Participants who die through Day 29 and Day 60

Time frame:
Up to Day 29 and Day 60
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Die (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)
Percentage of ParticipantsPhase 3 Cohort 1: Placebo - CriticalPhase 3 Cohort 1: Sarilumab 200mg IV - CriticalPhase 3 Cohort 1: Sarilumab 400mg IV - Critical
Through Day 2941.9 (29.7 to 54.2)33.7 (24.6 to 42.7)36.4 (28.2 to 44.6)
Through Day 6051.6 (39.2 to 64.1)37.5 (28.2 to 46.8)39.4 (31.1 to 47.7)
Statistical analysis
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 200mg IV - Critical · Cochran-Mantel-Haenszel · p = 0.3217 (P-value based on stratified Cochran-Mantel-Haenszel test using the strata Use of Steroids at Baseline.) · Risk difference (rd): -7.7 · 95% CI -22.8 to 7.2
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 400mg IV - Critical · Cochran-Mantel-Haenszel · p = 0.4630 (P-value based on stratified Cochran-Mantel-Haenszel test using the strata Use of Steroids at Baseline.) · Risk difference (rd): -5.5 · 95% CI -20.2 to 8.7
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 200mg IV - Critical · Cochran-Mantel-Haenszel · p = 0.0971 (P-value based on stratified Cochran-Mantel-Haenszel test using the strata Use of Steroids at Baseline.) · Risk difference (rd): -13.3 · 95% CI -28.2 to 2.3
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 400mg IV - Critical · Cochran-Mantel-Haenszel · p = 0.1193 (P-value based on stratified Cochran-Mantel-Haenszel test using the strata Use of Steroids at Baseline.) · Risk difference (rd): -11.9 · 95% CI -26.4 to 2.9
SecondaryPercentage of Participants Who Die (Phase 3 Cohort 1: Critical ITT)

Percentage of Participants who die through Day 29 and Day 60

Time frame:
Up to Day 29 and Day 60
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Die (Phase 3 Cohort 1: Critical ITT)
Percentage of ParticipantsPhase 3 Cohort 1: Placebo - CriticalPhase 3 Cohort 1: Sarilumab 200mg IV - CriticalPhase 3 Cohort 1: Sarilumab 400mg IV - Critical
Through Day 2925.3 (18.8 to 31.8)24.8 (19.4 to 30.2)30.5 (25.6 to 35.4)
Through Day 6034.7 (27.6 to 41.9)28.9 (23.2 to 34.6)33.7 (28.7 to 38.8)
Statistical analysis
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 200mg IV - Critical · Cochran-Mantel-Haenszel · p = 0.8844 (P-value based on stratified Cochran-Mantel-Haenszel test using the strata Use of Steroids at Baseline.) · Risk difference (rd): -0.6 · 95% CI -9.3 to 7.7
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 400mg IV - Critical · Cochran-Mantel-Haenszel · p = 0.2247 (P-value based on stratified Cochran-Mantel-Haenszel test using the strata Use of Steroids at Baseline.) · Risk difference (rd): 5.2 · 95% CI -3.3 to 13.0
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 200mg IV - Critical · Cochran-Mantel-Haenszel · p = 0.2102 (P-value based on stratified Cochran-Mantel-Haenszel test using the strata Use of Steroids at Baseline.) · Risk difference (rd): -13.3 · 95% CI -28.2 to 2.3
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 400mg IV - Critical · Cochran-Mantel-Haenszel · p = 0.8292 (P-value based on stratified Cochran-Mantel-Haenszel test using the strata Use of Steroids at Baseline.) · Risk difference (rd): -11.9 · 95% CI -26.4 to 2.9
SecondaryPercentage of Participants Alive Not Receiving Mechanical Ventilation or ECMO at Day 22 (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)

Percentage of participants alive not receiving mechanical ventilation or ECMO at Day 22 (Phase 3 Cohort 1)

Time frame:
At Day 22
Reported as:
Number · Percentage of Participants
Percentage of Participants Alive Not Receiving Mechanical Ventilation or ECMO at Day 22 (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)
Percentage of ParticipantsPhase 3 Cohort 1: Placebo - CriticalPhase 3 Cohort 1: Sarilumab 200mg IV - CriticalPhase 3 Cohort 1: Sarilumab 400mg IV - Critical
Percentage of Participants Alive Not Receiving Mechanical Ventilation or ECMO at Day 22 (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)35.5 (23.6 to 47.4)46.2 (36.6 to 55.7)44.7 (36.2 to 53.2)
Statistical analysis
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 200mg IV - Critical · Cochran-Mantel-Haenszel · p = 0.2203 (P-value based on stratified Cochran-Mantel-Haenszel test using the strata Use of Steroids at Baseline.) · Risk difference (rd): 9.8 · 95% CI -6.0 to 24.3
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 400mg IV - Critical · Cochran-Mantel-Haenszel · p = 0.2483 (P-value based on stratified Cochran-Mantel-Haenszel test using the strata Use of Steroids at Baseline.) · Risk difference (rd): 8.8 · 95% CI -6.1 to 22.6
SecondaryPercentage of Participants With at Least a 2-point Improvement in Clinical Status From Baseline to Day 22 Using the 7-point Ordinal Scale (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)

Percentage of participants with at least a 2-point improvement in clinical status from baseline to Day 22 using the 7-point ordinal scale. The ordinal scale is an assessment of the clinical status of a participant. The 7-point ordinal scale is as follows: 1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity

Time frame:
At Day 22
Reported as:
Number · Percentage of Participants
Percentage of Participants With at Least a 2-point Improvement in Clinical Status From Baseline to Day 22 Using the 7-point Ordinal Scale (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)
Percentage of ParticipantsPhase 3 Cohort 1: Placebo - CriticalPhase 3 Cohort 1: Sarilumab 200mg IV - CriticalPhase 3 Cohort 1: Sarilumab 400mg IV - Critical
Percentage of Participants With at Least a 2-point Improvement in Clinical Status From Baseline to Day 22 Using the 7-point Ordinal Scale (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)33.9 (22.1 to 45.7)38.5 (29.1 to 47.8)40.2 (31.8 to 48.5)
Statistical analysis
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 200mg IV - Critical · Cochran-Mantel-Haenszel · p = 0.6020 (P-value based on stratified Cochran-Mantel-Haenszel test using the strata Use of Steroids at Baseline.) · Risk difference (rd): 4.1 · 95% CI -11.2 to 18.5
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 400mg IV - Critical · Cochran-Mantel-Haenszel · p = 0.4342 (P-value based on stratified Cochran-Mantel-Haenszel test using the strata Use of Steroids at Baseline.) · Risk difference (rd): 5.9 · 95% CI -8.9 to 19.5
SecondaryPercentage of Participants Alive Not Receiving Mechanical Ventilation or ECMO at Day 22 (Phase 3 Cohort 1: Critical ITT)

Percentage of participants alive not receiving mechanical ventilation or ECMO at Day 22 (Phase 3 Cohort 1)

Time frame:
At Day 22
Reported as:
Number · Percentage of Participants
Percentage of Participants Alive Not Receiving Mechanical Ventilation or ECMO at Day 22 (Phase 3 Cohort 1: Critical ITT)
Percentage of ParticipantsPhase 3 Cohort 1: Placebo - CriticalPhase 3 Cohort 1: Sarilumab 200mg IV - CriticalPhase 3 Cohort 1: Sarilumab 400mg IV - Critical
Percentage of Participants Alive Not Receiving Mechanical Ventilation or ECMO at Day 22 (Phase 3 Cohort 1: Critical ITT)58.8 (51.4 to 66.2)63.6 (57.6 to 69.7)55.9 (50.6 to 61.2)
Statistical analysis
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 200mg IV - Critical · Cochran-Mantel-Haenszel · p = 0.2896 (P-value based on stratified Cochran-Mantel-Haenszel test using the strata Use of Steroids at Baseline.) · Risk difference (rd): 5.2 · 95% CI -4.3 to 14.7
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 400mg IV - Critical · Cochran-Mantel-Haenszel · p = 0.5355 (P-value based on stratified Cochran-Mantel-Haenszel test using the strata Use of Steroids at Baseline.) · Risk difference (rd): -2.9 · 95% CI -11.8 to 6.2
SecondaryPercentage of Participants With at Least a 2-point Improvement in Clinical Status From Baseline to Day 22 Using the 7-point Ordinal Scale (Phase 3 Cohort 1: Critical ITT)

Percentage of participants with at least a 2-point improvement in clinical status from baseline to Day 22 using the 7-point ordinal scale. The ordinal scale is an assessment of the clinical status of a participant. The 7-point ordinal scale is as follows: 1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity

Time frame:
At Day 22
Reported as:
Number · Percentage of Participants
Percentage of Participants With at Least a 2-point Improvement in Clinical Status From Baseline to Day 22 Using the 7-point Ordinal Scale (Phase 3 Cohort 1: Critical ITT)
Percentage of ParticipantsPhase 3 Cohort 1: Placebo - CriticalPhase 3 Cohort 1: Sarilumab 200mg IV - CriticalPhase 3 Cohort 1: Sarilumab 400mg IV - Critical
Percentage of Participants With at Least a 2-point Improvement in Clinical Status From Baseline to Day 22 Using the 7-point Ordinal Scale (Phase 3 Cohort 1: Critical ITT)52.4 (44.8 to 59.9)52.5 (46.2 to 58.8)47.6 (42.3 to 53.0)
Statistical analysis
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 200mg IV - Critical · Cochran-Mantel-Haenszel · p = 0.9210 (P-value based on stratified Cochran-Mantel-Haenszel test using the strata Use of Steroids at Baseline.) · Risk difference (rd): 0.5 · 95% CI -9.2 to 10.2
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 400mg IV - Critical · Cochran-Mantel-Haenszel · p = 0.3174 (P-value based on stratified Cochran-Mantel-Haenszel test using the strata Use of Steroids at Baseline.) · Risk difference (rd): -4.7 · 95% CI -13.8 to 4.5
SecondaryTime to at Least 1-point Improvement in Clinical Status Assessment on the 7-point Ordinal Scale (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)

The ordinal scale is an assessment of the clinical status of a participant. The 7-point ordinal scale is as follows: 1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity

Time frame:
Up to day 29
Reported as:
Median · Days
Time to at Least 1-point Improvement in Clinical Status Assessment on the 7-point Ordinal Scale (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)
DaysPhase 3 Cohort 1: Placebo - CriticalPhase 3 Cohort 1: Sarilumab 200mg IV - CriticalPhase 3 Cohort 1: Sarilumab 400mg IV - Critical
Time to at Least 1-point Improvement in Clinical Status Assessment on the 7-point Ordinal Scale (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)NA (NA to NA)27.0 (18.0 to NA)NA (18.0 to NA)
Statistical analysis
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 200mg IV - Critical · Log Rank · p = 0.0705 (P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).) · Hazard ratio (hr): 1.62 · 95% CI 0.98 to 2.66
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 400mg IV - Critical · Log Rank · p = 0.1800 (P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).) · Hazard ratio (hr): 1.50 · 95% CI 0.92 to 2.43
SecondaryTime to at Least 1-point Improvement in Clinical Status Assessment on the 7-point Ordinal Scale (Phase 3 Cohort 1: Critical ITT)

The ordinal scale is an assessment of the clinical status of a participant. The 7-point ordinal scale is as follows: 1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity

Time frame:
Up to day 29
Reported as:
Median · Days
Time to at Least 1-point Improvement in Clinical Status Assessment on the 7-point Ordinal Scale (Phase 3 Cohort 1: Critical ITT)
DaysPhase 3 Cohort 1: Placebo - CriticalPhase 3 Cohort 1: Sarilumab 200mg IV - CriticalPhase 3 Cohort 1: Sarilumab 400mg IV - Critical
Time to at Least 1-point Improvement in Clinical Status Assessment on the 7-point Ordinal Scale (Phase 3 Cohort 1: Critical ITT)19.5 (13.0 to NA)16.0 (12.0 to 20.0)18.0 (14.0 to 24.0)
Statistical analysis
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 200mg IV - Critical · Log Rank · p = 0.1831 (P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).) · Hazard ratio (hr): 1.18 · 95% CI 0.91 to 1.52
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 400mg IV - Critical · Log Rank · p = 0.8770 (P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).) · Hazard ratio (hr): 1.05 · 95% CI 0.82 to 1.34
SecondaryTime to at Least 1-point Improvement in Clinical Status Assessment on the 7-point Ordinal Scale (Phase 3 Cohort 2)

The ordinal scale is an assessment of the clinical status of a participant. The 7-point ordinal scale is as follows: 1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity

Time frame:
Up to day 29
Reported as:
Median · Days
Time to at Least 1-point Improvement in Clinical Status Assessment on the 7-point Ordinal Scale (Phase 3 Cohort 2)
DaysPhase 3 Cohort 2: PlaceboPhase 3 Cohort 2: Sarilumab 800mg IV
Time to at Least 1-point Improvement in Clinical Status Assessment on the 7-point Ordinal Scale (Phase 3 Cohort 2)17.0 (6.0 to 26.0)15.0 (9.0 to 25.0)
Statistical analysis
  • Phase 3 Cohort 2: Placebo vs Phase 3 Cohort 2: Sarilumab 800mg IV · Log Rank · p = 0.7103 (P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).) · Hazard ratio (hr): 0.85 · 95% CI 0.35 to 2.06
SecondaryTime to at Least 2-point Improvement in Clinical Status Assessment on the 7-point Ordinal Scale (Phase 3 Cohort 1)

The ordinal scale is an assessment of the clinical status of a participant. The 7-point ordinal scale is as follows: 1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity

Time frame:
Up to day 29
Reported as:
Median · days
Time to at Least 2-point Improvement in Clinical Status Assessment on the 7-point Ordinal Scale (Phase 3 Cohort 1)
daysPhase 3 Cohort 1: Placebo - CriticalPhase 3 Cohort 1: Sarilumab 200mg IV - CriticalPhase 3 Cohort 1: Sarilumab 400mg IV - Critical
Time to at Least 2-point Improvement in Clinical Status Assessment on the 7-point Ordinal Scale (Phase 3 Cohort 1)NA (NA to NA)NA (21.0 to NA)NA (21.0 to NA)
Statistical analysis
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 200mg IV - Critical · Log Rank · p = 0.1512 (P-value from stratified log-rank test) · Hazard ratio (hr): 1.47 · 95% CI 0.89 to 2.43
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 400mg IV - Critical · Log Rank · p = 0.2952 (P-value from stratified log-rank test) · Hazard ratio (hr): 1.38 · 95% CI 0.85 to 2.24
SecondaryTime to at Least 2-point Improvement in Clinical Status Assessment on the 7-point Ordinal Scale (Phase 3 Cohort 1: Critical ITT)

The ordinal scale is an assessment of the clinical status of a participant. The 7-point ordinal scale is as follows: 1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity

Time frame:
Up to day 29
Reported as:
Median · days
Time to at Least 2-point Improvement in Clinical Status Assessment on the 7-point Ordinal Scale (Phase 3 Cohort 1: Critical ITT)
daysPhase 3 Cohort 1: Placebo - CriticalPhase 3 Cohort 1: Sarilumab 200mg IV - CriticalPhase 3 Cohort 1: Sarilumab 400mg IV - Critical
Time to at Least 2-point Improvement in Clinical Status Assessment on the 7-point Ordinal Scale (Phase 3 Cohort 1: Critical ITT)22.0 (16.0 to NA)19.0 (16.0 to 24.0)23.0 (18.0 to NA)
Statistical analysis
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 200mg IV - Critical · Log Rank · p = 0.2297 (P-value from stratified log-rank test) · Hazard ratio (hr): 1.16 · 95% CI 0.89 to 1.50
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 400mg IV - Critical · Log Rank · p = 0.8651 (P-value from stratified log-rank test) · Hazard ratio (hr): 1.01 · 95% CI 0.79 to 1.30
SecondaryPercentage of Participants Receiving Mechanical Ventilation or ECMO at Day 22 (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)
Time frame:
Day 22
Reported as:
Number · Percentage of Participants
Percentage of Participants Receiving Mechanical Ventilation or ECMO at Day 22 (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)
Percentage of ParticipantsPhase 3 Cohort 1: Placebo - CriticalPhase 3 Cohort 1: Sarilumab 200mg IV - CriticalPhase 3 Cohort 1: Sarilumab 400mg IV - Critical
Percentage of Participants Receiving Mechanical Ventilation or ECMO at Day 22 (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)25.8 (14.9 to 36.7)24.0 (15.8 to 32.3)23.5 (16.3 to 30.7)
Statistical analysis
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 200mg IV - Critical · Cochran-Mantel-Haenszel · p = 0.8864 (P-value based on stratified Cochran-Mantel-Haenszel test using the strata Use of Steroids at Baseline.) · Risk difference (rd): -1.0 · 95% CI -15.2 to 12.1
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 400mg IV - Critical · Cochran-Mantel-Haenszel · p = 0.7500 (P-value based on stratified Cochran-Mantel-Haenszel test using the strata Use of Steroids at Baseline.) · Risk difference (rd): -2.1 · 95% CI -15.8 to 10.1
SecondaryPercentage of Participants Receiving Mechanical Ventilation or ECMO at Day 22 (Phase 3 Cohort 1: Critical ITT)
Time frame:
Day 22
Reported as:
Number · Percentage of Participants
Percentage of Participants Receiving Mechanical Ventilation or ECMO at Day 22 (Phase 3 Cohort 1: Critical ITT)
Percentage of ParticipantsPhase 3 Cohort 1: Placebo - CriticalPhase 3 Cohort 1: Sarilumab 200mg IV - CriticalPhase 3 Cohort 1: Sarilumab 400mg IV - Critical
Percentage of Participants Receiving Mechanical Ventilation or ECMO at Day 22 (Phase 3 Cohort 1: Critical ITT)17.1 (11.4 to 22.7)15.7 (11.1 to 20.3)17.5 (13.4 to 21.5)
Statistical analysis
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 200mg IV - Critical · Cochran-Mantel-Haenszel · p = 0.6858 (P-value based on stratified Cochran-Mantel-Haenszel test using the strata Use of Steroids at Baseline.) · Risk difference (rd): -1.5 · 95% CI -9.1 to 5.6
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 400mg IV - Critical · Cochran-Mantel-Haenszel · p = 0.9173 (P-value based on stratified Cochran-Mantel-Haenszel test using the strata Use of Steroids at Baseline.) · Risk difference (rd): 0.4 · 95% CI -7.0 to 7.0
SecondaryPercentage of Patients Discharged and Alive (Phase 3 Cohort 1)

Percentage of Patients Discharged and Alive at Day 22

Time frame:
At Day 22
Reported as:
Number · Percentage of Participants
Percentage of Patients Discharged and Alive (Phase 3 Cohort 1)
Percentage of ParticipantsPhase 3 Cohort 1: Placebo - CriticalPhase 3 Cohort 1: Sarilumab 200mg IV - CriticalPhase 3 Cohort 1: Sarilumab 400mg IV - Critical
Percentage of Patients Discharged and Alive (Phase 3 Cohort 1)22.6 (12.2 to 33.0)26.9 (18.4 to 35.4)26.5 (19.0 to 34.0)
Statistical analysis
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 200mg IV - Critical · Cochran-Mantel-Haenszel · p = 0.5239 (P-value based on stratified Cochran-Mantel-Haenszel test using the strata Use of Steroids at Baseline.) · Risk difference (rd): 4.5 · 95% CI -9.7 to 17.3
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 400mg IV - Critical · Cochran-Mantel-Haenszel · p = 0.5809 (P-value based on stratified Cochran-Mantel-Haenszel test using the strata Use of Steroids at Baseline.) · Risk difference (rd): 3.7 · 95% CI -10.0 to 15.6
SecondaryPercentage of Participants Discharged and Alive at Day 22 (Phase 3 Cohort 1: Critical ITT)

Percentage of Participants Discharged and Alive at Day 22

Time frame:
At Day 22
Reported as:
Number · Percentage of Participants
Percentage of Participants Discharged and Alive at Day 22 (Phase 3 Cohort 1: Critical ITT)
Percentage of ParticipantsPhase 3 Cohort 1: Placebo - CriticalPhase 3 Cohort 1: Sarilumab 200mg IV - CriticalPhase 3 Cohort 1: Sarilumab 400mg IV - Critical
Percentage of Participants Discharged and Alive at Day 22 (Phase 3 Cohort 1: Critical ITT)47.6 (40.1 to 55.2)47.5 (41.2 to 53.8)42.6 (37.3 to 47.9)
Statistical analysis
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 200mg IV - Critical · Cochran-Mantel-Haenszel · p = 0.9343 (P-value based on stratified Cochran-Mantel-Haenszel test using the strata Use of Steroids at Baseline.) · Risk difference (rd): 0.4 · 95% CI -9.3 to 10.1
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 400mg IV - Critical · Cochran-Mantel-Haenszel · p = 0.2822 (P-value based on stratified Cochran-Mantel-Haenszel test using the strata Use of Steroids at Baseline.) · Risk difference (rd): -5.0 · 95% CI -14.1 to 4.1
SecondaryTime to Recovery (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)

Phase 3 Cohort 1 Time to Recovery (Discharged, or Alive without Supplemental Oxygen Use or at Pre-COVID Oxygen Use)

Time frame:
Up to day 29
Reported as:
Median · days
Time to Recovery (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)
daysPhase 3 Cohort 1: Placebo - CriticalPhase 3 Cohort 1: Sarilumab 200mg IV - CriticalPhase 3 Cohort 1: Sarilumab 400mg IV - Critical
Time to Recovery (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)NA (NA to NA)NA (29.0 to NA)NA (28.0 to NA)
Statistical analysis
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 200mg IV - Critical · Log Rank · p = 0.4519 (P-value from stratified log-rank test) · Hazard ratio (hr): 1.28 · 95% CI 0.75 to 2.18
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 400mg IV - Critical · Log Rank · p = 0.2818 (P-value from stratified log-rank test) · Hazard ratio (hr): 1.35 · 95% CI 0.81 to 2.24
SecondaryTime to Recovery (Phase 3 Cohort 1: Critical ITT)

Phase 3 Cohort 1 Time to Recovery (Discharged, or Alive without Supplemental Oxygen Use or at Pre-COVID Oxygen Use)

Time frame:
Up to day 29
Reported as:
Median · days
Time to Recovery (Phase 3 Cohort 1: Critical ITT)
daysPhase 3 Cohort 1: Placebo - CriticalPhase 3 Cohort 1: Sarilumab 200mg IV - CriticalPhase 3 Cohort 1: Sarilumab 400mg IV - Critical
Time to Recovery (Phase 3 Cohort 1: Critical ITT)25.5 (18.0 to NA)23.0 (17.0 to NA)27.0 (22.0 to NA)
Statistical analysis
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 200mg IV - Critical · Log Rank · p = 0.4674 (P-value from stratified log-rank test) · Hazard ratio (hr): 1.09 · 95% CI 0.84 to 1.43
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 400mg IV - Critical · Log Rank · p = 0.8503 (P-value from stratified log-rank test.) · Hazard ratio (hr): 1.00 · 95% CI 0.77 to 1.28
SecondaryTime to Recovery (Phase 3 Cohort 2)

Time to Recovery (Discharged, or Alive without Supplemental Oxygen Use or at Pre-COVID Oxygen Use)

Time frame:
Up to day 29
Reported as:
Median · days
Time to Recovery (Phase 3 Cohort 2)
daysPhase 3 Cohort 2: PlaceboPhase 3 Cohort 2: Sarilumab 800mg IV
Time to Recovery (Phase 3 Cohort 2)23.0 (12.0 to NA)22.0 (13.0 to NA)
Statistical analysis
  • Phase 3 Cohort 2: Placebo vs Phase 3 Cohort 2: Sarilumab 800mg IV · Log Rank · p = 0.6156 (P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).) · Hazard ratio (hr): 0.79 · 95% CI 0.31 to 2.02
SecondaryTime to Death (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)

Phase 3 Cohort 1 Time to Death (All-Cause Mortality)

Time frame:
Up to day 60
Reported as:
Median · days
Time to Death (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)
daysPhase 3 Cohort 1: Placebo - CriticalPhase 3 Cohort 1: 200mg IV - CriticalPhase 3 Cohort 1: Sarilumab 400mg IV - Critical
Time to Death (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)41.0 (17.0 to NA)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: 200mg IV - Critical · Log Rank · p = 0.0843 (P-value from stratified log-rank test) · Hazard ratio (hr): 0.65 · 95% CI 0.41 to 1.03
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 400mg IV - Critical · Log Rank · p = 0.1576 (P-value from stratified log-rank test) · Hazard ratio (hr): 0.69 · 95% CI 0.44 to 1.07
SecondaryTime to Death (Phase 3 Cohort 1: Critical ITT)

Time to Death (All-Cause Mortality)

Time frame:
Up to day 60
Reported as:
Median · days
Time to Death (Phase 3 Cohort 1: Critical ITT)
daysPhase 3 Cohort 1: Placebo - CriticalPhase 3 Cohort 1: Sarilumab 200mg IV - CriticalPhase 3 Cohort 1: Sarilumab 400mg IV - Critical
Time to Death (Phase 3 Cohort 1: Critical ITT)NA (NA to NA)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 200mg IV - Critical · Log Rank · p = 0.1980 (P-value from stratified log-rank test) · Hazard ratio (hr): 0.81 · 95% CI 0.57 to 1.14
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 400mg IV - Critical · Log Rank · p = 0.7973 (P-value from stratified log-rank test.) · Hazard ratio (hr): 1.00 · 95% CI 0.73 to 1.36
SecondaryTime to Death (Phase 3 Cohort 2)

Time to Death (All-Cause Mortality)

Time frame:
Up to day 60
Reported as:
Median · days
Time to Death (Phase 3 Cohort 2)
daysPhase 3 Cohort 2: PlaceboPhase 3 Cohort 2: Sarilumab 800mg IV
Time to Death (Phase 3 Cohort 2)NA (17.0 to NA)NA (NA to NA)
Statistical analysis
  • Phase 3 Cohort 2: Placebo vs Phase 3 Cohort 2: Sarilumab 800mg IV · Log Rank · p = 0.5023 (P-value based on log-rank test stratified by use of systemic corticosteroids for COVID-19 (Yes, No).) · Hazard ratio (hr): 0.60 · 95% CI 0.13 to 2.75
SecondaryNumber of Ventilator-Free Days (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)

Number of Ventilator-Free days up to Day 29 (Phase 3 Cohort 1)

Time frame:
Days 8, 15, 22 and 29
Reported as:
Mean · days
Number of Ventilator-Free Days (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)
daysPhase 3 Cohort 1: Placebo - CriticalPhase 3 Cohort 1: Sarilumab 200mg IV - CriticalPhase 3 Cohort 1: Sarilumab 400mg IV - Critical
Ventilator-free days up to Day 80.6 ± 1.40.8 ± 1.70.4 ± 1.2
Ventilator-free days up to Day 152.2 ± 4.02.8 ± 4.42.2 ± 3.7
Ventilator-free days up to Day 224.3 ± 6.85.5 ± 7.34.8 ± 6.6
Ventilator-free days up to Day 296.9 ± 9.98.7 ± 10.48.0 ± 9.6
Statistical analysis
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 200mg IV - Critical · t-test, 2 sided · p = 0.2804 (p-value using two-sample t-test) · Risk difference (rd): 0.3 · 95% CI -0.2 to 0.8
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 400mg IV - Critical · t-test, 2 sided · p = 0.5023 (p-value using two-sample t-test) · Risk difference (rd): -0.1 · 95% CI -0.5 to 0.3
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 200mg IV - Critical · t-test, 2 sided · p = 0.3821 (p-value using two-sample t-test) · Risk difference (rd): 0.6 · 95% CI -0.7 to 1.9
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 400mg IV - Critical · t-test, 2 sided · p = 0.9737 (p-value using two-sample t-test) · Risk difference (rd): 0.0 · 95% CI -1.2 to 1.1
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 200mg IV - Critical · t-test, 2 sided · p = 0.3179 (p-value using two-sample t-test) · Risk difference (rd): 1.2 · 95% CI -1.1 to 3.4
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 400mg IV - Critical · t-test, 2 sided · p = 0.6302 (p-value using two-sample t-test) · Risk difference (rd): 0.5 · 95% CI -1.5 to 2.5
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 200mg IV - Critical · t-test, 2 sided · p = 0.2862 (p-value using two-sample t-test) · Risk difference (rd): 1.8 · 95% CI -1.5 to 5.0
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 400mg IV - Critical · t-test, 2 sided · p = 0.4509 (p-value using two-sample t-test) · Risk difference (rd): 1.1 · 95% CI -1.8 to 4.1
SecondaryNumber of Ventilator-Free Days (Phase 3 Cohort 1: Critical ITT)

Number of Ventilator-Free days up to Day 29 (Phase 3 Cohort 1)

Time frame:
Days 8, 15, 22 and 29
Reported as:
Mean · days
Number of Ventilator-Free Days (Phase 3 Cohort 1: Critical ITT)
daysPhase 3 Cohort 1: Placebo - CriticalPhase 3 Cohort 1: Sarilumab 200mg IV - CriticalPhase 3 Cohort 1: Sarilumab 400mg IV - Critical
Ventilator-free days up to Day 83.6 ± 3.33.5 ± 3.33.2 ± 3.3
Ventilator-free days up to Day 157.2 ± 6.57.2 ± 6.46.4 ± 6.4
Ventilator-free days up to Day 2211.1 ± 9.711.3 ± 9.49.9 ± 9.4
Ventilator-free days up to Day 2915.3 ± 12.815.5 ± 12.413.9 ± 12.5
Statistical analysis
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 200mg IV - Critical · t-test, 2 sided · p = 0.5640 (p-value using two-sample t-test) · Risk difference (rd): -0.2 · 95% CI -0.8 to 0.5
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 400mg IV - Critical · t-test, 2 sided · p = 0.1602 (p-value using two-sample t-test) · Risk difference (rd): -0.4 · 95% CI -1.0 to 0.2
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 200mg IV - Critical · t-test, 2 sided · p = 0.9144 (p-value using two-sample t-test) · Risk difference (rd): -0.1 · 95% CI -1.3 to 1.2
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 400mg IV - Critical · t-test, 2 sided · p = 0.1450 (p-value using two-sample t-test) · Risk difference (rd): -0.9 · 95% CI -2.1 to 0.3
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 200mg IV - Critical · t-test, 2 sided · p = 0.8378 (p-value using two-sample t-test) · Risk difference (rd): 0.2 · 95% CI -1.7 to 2.1
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 400mg IV - Critical · t-test, 2 sided · p = 0.1988 (p-value using two-sample t-test) · Risk difference (rd): -1.2 · 95% CI -2.9 to 0.6
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 200mg IV - Critical · t-test, 2 sided · p = 0.8556 (p-value using two-sample t-test) · Risk difference (rd): 0.2 · 95% CI -2.2 to 2.7
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 400mg IV - Critical · t-test, 2 sided · p = 0.2630 (p-value using two-sample t-test) · Risk difference (rd): -1.3 · 95% CI -3.7 to 1.0
SecondaryNumber of Days of Hospitalization Among Survivors (Phase 3 Cohort 1)

Number of days of hospitalization among survivors (Phase 3 Cohort 1)

Time frame:
Days 8, 15, 22 and 29
Reported as:
Mean · days
Number of Days of Hospitalization Among Survivors (Phase 3 Cohort 1)
daysPhase 3 Cohort 1: Placebo - CriticalPhase 3 Cohort 1: Sarilumab 200mg IV - CriticalPhase 3 Cohort 1: Sarilumab 400mg IV - Critical
Hospitalized up to Day 87.7 ± 0.97.8 ± 0.68.0 ± 0.2
Hospitalized up to Day 1514.5 ± 1.514.4 ± 1.514.5 ± 1.3
Hospitalized up to Day 2220.7 ± 2.321.6 ± 1.321.1 ± 1.7
Hospitalized up to Day 2928.3 ± 1.828.5 ± 1.428.2 ± 1.6
Statistical analysis
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 200mg IV - Critical · t-test, 2 sided · p = 0.3662 (p-value using two-sample t-test) · Mean difference (net): 0.2 · 95% CI -0.2 to 0.5
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 400mg IV - Critical · t-test, 2 sided · p = 0.0820 (p-value using two-sample t-test) · Mean difference (net): 0.3 · 95% CI 0.0 to 0.6
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 200mg IV - Critical · t-test, 2 sided · p = 0.6984 (p-value using two-sample t-test) · Mean difference (net): -0.1 · 95% CI -0.9 to 0.6
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 400mg IV - Critical · t-test, 2 sided · p = 0.9833 (p-value using two-sample t-test) · Mean difference (net): 0.0 · 95% CI -0.6 to 0.6
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 200mg IV - Critical · t-test, 2 sided · p = 0.1436 (p-value using two-sample t-test) · Mean difference (net): 0.9 · 95% CI -0.3 to 2.0
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 400mg IV - Critical · t-test, 2 sided · p = 0.4190 (p-value using two-sample t-test) · Mean difference (net): 0.4 · 95% CI -0.6 to 1.4
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 200mg IV - Critical · t-test, 2 sided · p = 0.6520 (p-value using two-sample t-test) · Mean difference (net): 0.2 · 95% CI -0.7 to 1.2
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 400mg IV - Critical · t-test, 2 sided · p = 0.8010 (p-value using two-sample t-test) · Mean difference (net): -0.1 · 95% CI -1.1 to 0.9
SecondaryNumber of Days of Hospitalization Among Survivors (Phase 3 Cohort 1: Critical ITT)

Number of days of hospitalization among survivors (Phase 3 Cohort 1: Critical ITT population)

Time frame:
Days 8, 15, 22 and 29
Reported as:
Mean · days
Number of Days of Hospitalization Among Survivors (Phase 3 Cohort 1: Critical ITT)
daysPhase 3 Cohort 1: Placebo - CriticalPhase 3 Cohort 1: Sarilumab 200mg IV - CriticalPhase 3 Cohort 1: Sarilumab 400mg IV - Critical
Hospitalized up to Day 87.5 ± 1.27.4 ± 1.37.6 ± 1.1
Hospitalized up to Day 1513.7 ± 2.013.8 ± 1.913.8 ± 2.0
Hospitalized up to Day 2220.8 ± 2.021.1 ± 1.821.2 ± 1.7
Hospitalized up to Day 2928.4 ± 1.428.2 ± 1.828.1 ± 1.8
Statistical analysis
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 200mg IV - Critical · t-test, 2 sided · p = 0.3724 (p-value using two-sample t-test) · Mean difference (net): -0.1 · 95% CI -0.4 to 0.2
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 400mg IV - Critical · t-test, 2 sided · p = 0.7034 (p-value using two-sample t-test) · Mean difference (net): 0.0 · 95% CI -0.2 to 0.3
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 200mg IV - Critical · t-test, 2 sided · p = 0.5841 (p-value using two-sample t-test) · Mean difference (net): 0.2 · 95% CI -0.4 to 0.7
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 400mg IV - Critical · t-test, 2 sided · p = 0.6648 (p-value using two-sample t-test) · Mean difference (net): 0.1 · 95% CI -0.4 to 0.6
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 200mg IV - Critical · t-test, 2 sided · p = 0.4624 (p-value using two-sample t-test) · Mean difference (net): 0.3 · 95% CI -0.4 to 1.0
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 400mg IV - Critical · t-test, 2 sided · p = 0.2546 (p-value using two-sample t-test) · Mean difference (net): 0.4 · 95% CI -0.3 to 1.0
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 200mg IV - Critical · t-test, 2 sided · p = 0.5312 (p-value using two-sample t-test) · Mean difference (net): -0.2 · 95% CI -1.0 to 0.5
  • Phase 3 Cohort 1: Placebo - Critical vs Phase 3 Cohort 1: Sarilumab 400mg IV - Critical · t-test, 2 sided · p = 0.3039 (p-value using two-sample t-test) · Mean difference (net): -0.4 · 95% CI -1.1 to 0.3
SecondaryNumber of Participants With Any Serious Adverse Event
Time frame:
Up to day 60
Reported as:
Count of participants · Participants
Number of Participants With Any Serious Adverse Event
ParticipantsPhase 2: PlaceboPhase 2: Sarilumab 200mg IVPhase 2: Sarilumab 400mg IVPhase 3 Cohort 1: Placebo - CriticalPhase 3 Cohort 1: Sarilumab 200mg IV - CriticalPhase 3 Cohort 1: Sarilumab 400mg IV - CriticalPhase 3 Cohort 1: Placebo - SeverePhase 3 Cohort 1: Sarilumab 200mg IV - SeverePhase 3 Cohort 1: Sarilumab 400mg IV - SeverePhase 3 Cohort 1: Placebo - MSODPhase 3 Cohort 1: Sarilumab 200mg IV - MSODPhase 3 Cohort 1: Sarilumab 400mg IV - MSODPhase 3 Cohort 1: Placebo - ImmunocompromisedPhase 3 Cohort 1: Sarilumab 200mg IV - ImmunocompromisedPhase 3 Cohort 1: Sarilumab 400mg IV - ImmunocompromisedPhase 3 Cohort 2: PlaceboPhase 3 Cohort 2: Sarilumab 800 mg IVPhase 3 Cohort 3: PlaceboPhase 3 Cohort 3: Sarilumab 800 mg IV
Number of Participants With Any Serious Adverse Event3990848911918311233027675836910511
SecondaryNumber of Participants With Grade 4 Neutropenia (ANC <500/mm3)

Grade 4 Neutropenia defined as Absolute Neutrophil Count (ANC) of less than 500 per cubic millimeter(mm3)

Time frame:
Up to day 60
Reported as:
Count of participants · Participants
Number of Participants With Grade 4 Neutropenia (ANC <500/mm3)
ParticipantsPhase 2: PlaceboPhase 2: Sarilumab 200mg IVPhase 2: Sarilumab 400mg IVPhase 3 Cohort 1: Placebo - CriticalPhase 3 Cohort 1: Sarilumab 200mg IV - CriticalPhase 3 Cohort 1: Sarilumab 400mg IV - CriticalPhase 3 Cohort 1: Placebo - SeverePhase 3 Cohort 1: Sarilumab 200mg IV - SeverePhase 3 Cohort 1: Sarilumab 400mg IV - SeverePhase 3 Cohort 1: Placebo - MSODPhase 3 Cohort 1: Sarilumab 200mg IV - MSODPhase 3 Cohort 1: Sarilumab 400mg IV - MSODPhase 3 Cohort 1: Placebo - ImmunocompromisedPhase 3 Cohort 1: Sarilumab 200mg IV - ImmunocompromisedPhase 3 Cohort 1: Sarilumab 400mg IV - ImmunocompromisedPhase 3 Cohort 2: PlaceboPhase 3 Cohort 2: Sarilumab 800 mg IVPhase 3 Cohort 3: PlaceboPhase 3 Cohort 3: Sarilumab 800 mg IV
Number of Participants With Grade 4 Neutropenia (ANC <500/mm3)0110210120020010100
SecondaryNumber of Participants With Severe or Life-threatening Bacterial, Invasive Fungal, or Opportunistic Infection
Time frame:
Up to day 60
Reported as:
Count of participants · Participants
Number of Participants With Severe or Life-threatening Bacterial, Invasive Fungal, or Opportunistic Infection
ParticipantsPhase 2: PlaceboPhase 2: Sarilumab 200mg IVPhase 2: Sarilumab 400mg IVPhase 3 Cohort 1: Placebo - CriticalPhase 3 Cohort 1: Sarilumab 200mg IV - CriticalPhase 3 Cohort 1: Sarilumab 400mg IV - CriticalPhase 3 Cohort 1: Placebo - SeverePhase 3 Cohort 1: Sarilumab 200mg IV - SeverePhase 3 Cohort 1: Sarilumab 400mg IV - SeverePhase 3 Cohort 1: Placebo - MSODPhase 3 Cohort 1: Sarilumab 200mg IV - MSODPhase 3 Cohort 1: Sarilumab 400mg IV - MSODPhase 3 Cohort 1: Placebo - ImmunocompromisedPhase 3 Cohort 1: Sarilumab 200mg IV - ImmunocompromisedPhase 3 Cohort 1: Sarilumab 400mg IV - ImmunocompromisedPhase 3 Cohort 2: PlaceboPhase 3 Cohort 2: Sarilumab 800 mg IVPhase 3 Cohort 3: PlaceboPhase 3 Cohort 3: Sarilumab 800 mg IV
Number of Participants With Severe or Life-threatening Bacterial, Invasive Fungal, or Opportunistic Infection14172536537222101630281433411
SecondaryNumber of Participants With Grade 4 Neutropenia and Concurrent Invasive Infection
Time frame:
Up to day 60
Reported as:
Count of participants · Participants
Number of Participants With Grade 4 Neutropenia and Concurrent Invasive Infection
ParticipantsPhase 2: PlaceboPhase 2: Sarilumab 200mg IVPhase 2: Sarilumab 400mg IVPhase 3 Cohort 1: Placebo - CriticalPhase 3 Cohort 1: Sarilumab 200mg IV - CriticalPhase 3 Cohort 1: Sarilumab 400mg IV - CriticalPhase 3 Cohort 1: Placebo - SeverePhase 3 Cohort 1: Sarilumab 200mg IV - SeverePhase 3 Cohort 1: Sarilumab 400mg IV - SeverePhase 3 Cohort 1: Placebo - MSODPhase 3 Cohort 1: Sarilumab 200mg IV - MSODPhase 3 Cohort 1: Sarilumab 400mg IV - MSODPhase 3 Cohort 1: Placebo - ImmunocompromisedPhase 3 Cohort 1: Sarilumab 200mg IV - ImmunocompromisedPhase 3 Cohort 1: Sarilumab 400mg IV - ImmunocompromisedPhase 3 Cohort 2: PlaceboPhase 3 Cohort 2: Sarilumab 800 mg IVPhase 3 Cohort 3: PlaceboPhase 3 Cohort 3: Sarilumab 800 mg IV
Number of Participants With Grade 4 Neutropenia and Concurrent Invasive Infection0000000000000000000
SecondaryNumber of Participants With Grade >=2 Infusion Related Reactions
Time frame:
Up to day 60
Reported as:
Count of participants · Participants
Number of Participants With Grade >=2 Infusion Related Reactions
ParticipantsPhase 2: PlaceboPhase 2: Sarilumab 200mg IVPhase 2: Sarilumab 400mg IVPhase 3 Cohort 1: Placebo - CriticalPhase 3 Cohort 1: Sarilumab 200mg IV - CriticalPhase 3 Cohort 1: Sarilumab 400mg IV - CriticalPhase 3 Cohort 1: Placebo - SeverePhase 3 Cohort 1: Sarilumab 200mg IV - SeverePhase 3 Cohort 1: Sarilumab 400mg IV - SeverePhase 3 Cohort 1: Placebo - MSODPhase 3 Cohort 1: Sarilumab 200mg IV - MSODPhase 3 Cohort 1: Sarilumab 400mg IV - MSODPhase 3 Cohort 1: Placebo - ImmunocompromisedPhase 3 Cohort 1: Sarilumab 200mg IV - ImmunocompromisedPhase 3 Cohort 1: Sarilumab 400mg IV - ImmunocompromisedPhase 3 Cohort 2: PlaceboPhase 3 Cohort 2: Sarilumab 800 mg IVPhase 3 Cohort 3: PlaceboPhase 3 Cohort 3: Sarilumab 800 mg IV
Number of Participants With Grade >=2 Infusion Related Reactions0011260021221001001
SecondaryNumber of Participants With Grade >=2 Hypersensitivity Reactions
Time frame:
Up to day 60
Reported as:
Count of participants · Participants
Number of Participants With Grade >=2 Hypersensitivity Reactions
ParticipantsPhase 2: PlaceboPhase 2: Sarilumab 200mg IVPhase 2: Sarilumab 400mg IVPhase 3 Cohort 1: Placebo - CriticalPhase 3 Cohort 1: Sarilumab 200mg IV - CriticalPhase 3 Cohort 1: Sarilumab 400mg IV - CriticalPhase 3 Cohort 1: Placebo - SeverePhase 3 Cohort 1: Sarilumab 200mg IV - SeverePhase 3 Cohort 1: Sarilumab 400mg IV - SeverePhase 3 Cohort 1: Placebo - MSODPhase 3 Cohort 1: Sarilumab 200mg IV - MSODPhase 3 Cohort 1: Sarilumab 400mg IV - MSODPhase 3 Cohort 1: Placebo - ImmunocompromisedPhase 3 Cohort 1: Sarilumab 200mg IV - ImmunocompromisedPhase 3 Cohort 1: Sarilumab 400mg IV - ImmunocompromisedPhase 3 Cohort 2: PlaceboPhase 3 Cohort 2: Sarilumab 800 mg IVPhase 3 Cohort 3: PlaceboPhase 3 Cohort 3: Sarilumab 800 mg IV
Number of Participants With Grade >=2 Hypersensitivity Reactions0001100100000000000
SecondaryNumber of Participants With Gastrointestinal Perforation
Time frame:
Up to day 60
Reported as:
Count of participants · Participants
Number of Participants With Gastrointestinal Perforation
ParticipantsPhase 2: PlaceboPhase 2: Sarilumab 200mg IVPhase 2: Sarilumab 400mg IVPhase 3 Cohort 1: Placebo - CriticalPhase 3 Cohort 1: Sarilumab 200mg IV - CriticalPhase 3 Cohort 1: Sarilumab 400mg IV - CriticalPhase 3 Cohort 1: Placebo - SeverePhase 3 Cohort 1: Sarilumab 200mg IV - SeverePhase 3 Cohort 1: Sarilumab 400mg IV - SeverePhase 3 Cohort 1: Placebo - MSODPhase 3 Cohort 1: Sarilumab 200mg IV - MSODPhase 3 Cohort 1: Sarilumab 400mg IV - MSODPhase 3 Cohort 1: Placebo - ImmunocompromisedPhase 3 Cohort 1: Sarilumab 200mg IV - ImmunocompromisedPhase 3 Cohort 1: Sarilumab 400mg IV - ImmunocompromisedPhase 3 Cohort 2: PlaceboPhase 3 Cohort 2: Sarilumab 800 mg IVPhase 3 Cohort 3: PlaceboPhase 3 Cohort 3: Sarilumab 800 mg IV
Number of Participants With Gastrointestinal Perforation0100100000100000000
SecondaryMean Observed Leukocyte Values Across Study Days (Phase 2)
Time frame:
Days 1, 4, 15 and 29
Reported as:
Mean · 10^9 cells/liter(L)
Mean Observed Leukocyte Values Across Study Days (Phase 2)
10^9 cells/liter(L)Phase 2: PlaceboPhase 2: Sarilumab 200mg IVPhase 2: Sarilumab 400mg IV
Day 18.95 ± 3.739.41 ± 4.6810.28 ± 6.47
Day 410.75 ± 5.549.00 ± 6.619.47 ± 6.91
Day 1512.44 ± 5.9413.10 ± 7.1712.10 ± 7.78
Day 2912.06 ± 6.7311.20 ± 5.8112.48 ± 6.90
SecondaryMean Observed Leukocyte Values Across Study Days (Phase 3)
Time frame:
Days 1, 4, 15 and 29
Reported as:
Mean · 10^9 cells/liter(L)
Mean Observed Leukocyte Values Across Study Days (Phase 3)
10^9 cells/liter(L)Phase 3 Cohort 1: Placebo - CriticalPhase 3 Cohort 1: Sarilumab 200mg IV - CriticalPhase 3 Cohort 1: Sarilumab 400mg IV - CriticalPhase 3 Cohort 1: Placebo - SeverePhase 3 Cohort 1: Sarilumab 200mg IV - SeverePhase 3 Cohort 1: Sarilumab 400mg IV - SeverePhase 3 Cohort 1: Placebo - MSODPhase 3 Cohort 1: Sarilumab 200mg IV - MSODPhase 3 Cohort 1: Sarilumab 400mg IV - MSODPhase 3 Cohort 1: Placebo - ImmunocompromisedPhase 3 Cohort 1: Sarilumab 200mg IV - ImmunocompromisedPhase 3 Cohort 1: Sarilumab 400mg IV - ImmunocompromisedPhase 3 Cohort 2: PlaceboPhase 3 Cohort 2: Sarilumab 800 mg IVPhase 3 Cohort 3: PlaceboPhase 3 Cohort 3: Sarilumab 800 mg IV
Day 1 (Baseline)10.18 ± 4.5710.51 ± 4.8310.52 ± 4.4427.83 ± 2.978.16 ± 3.428.38 ± 4.0612.01 ± 5.5712.98 ± 5.7212.35 ± 5.7814.26 ± 9.999.13 ± 5.1127.20 ± 5.2811.52 ± 3.5512.13 ± 5.278.80 ± 2.144.80 ± 1.84
Day 412.11 ± 5.499.47 ± 5.779.19 ± 5.827.93 ± 2.876.76 ± 3.926.89 ± 5.1013.53 ± 7.4411.62 ± 7.0511.25 ± 8.4213.48 ± 10.886.44 ± 2.686.50 ± 6.3612.15 ± 4.878.30 ± 3.879.96 ± 2.924.70 ± 3.54
Day 1512.03 ± 4.6811.26 ± 6.7910.47 ± 6.2810.58 ± 5.869.68 ± 4.8811.18 ± 10.5213.97 ± 5.5712.73 ± 7.2511.90 ± 8.8822.45 ± 17.058.12 ± 2.7512.84 ± 7.2111.70 ± 4.8110.68 ± 10.7614.45 ± 8.1216.40 ± 1.84
Day 2911.90 ± 6.0012.17 ± 7.4531.35 ± 194.417.81 ± 2.6611.56 ± 6.6711.72 ± 6.2810.22 ± 3.6211.15 ± 6.8410.50 ± 6.4418.30 ± 09.52 ± 5.4714.10 ± 11.0211.22 ± 8.677.43 ± 2.5728.44 ± 22.967.50 ± 5.09
SecondaryMean Observed Hemoglobin Values Across Study Days (Phase 2)
Time frame:
Days 1, 4, 15 and 29
Reported as:
Mean · grams/Liter (g/L)
Mean Observed Hemoglobin Values Across Study Days (Phase 2)
grams/Liter (g/L)Phase 2: PlaceboPhase 2: Sarilumab 200mg IVPhase 2: Sarilumab 400mg IV
Day 1 (Baseline)122.53 ± 20.65122.19 ± 19.75122.75 ± 20.27
Day 4120.30 ± 28.23122.79 ± 20.44122.61 ± 20.83
Day 15100.04 ± 22.39104.11 ± 21.88105.85 ± 22.67
Day 2990.48 ± 15.3096.00 ± 21.3698.20 ± 19.20
SecondaryMean Observed Hemoglobin Values Across Study Days (Phase 3)
Time frame:
Days 1, 4, 15 and 29
Reported as:
Mean · grams/Liter (g/L)
Mean Observed Hemoglobin Values Across Study Days (Phase 3)
grams/Liter (g/L)Phase 3 Cohort 1: Placebo - CriticalPhase 3 Cohort 1: Sarilumab 200mg IV - CriticalPhase 3 Cohort 1: Sarilumab 400mg IV - CriticalPhase 3 Cohort 1: Placebo - SeverePhase 3 Cohort 1: Sarilumab 200mg IV - SeverePhase 3 Cohort 1: Sarilumab 400mg IV - SeverePhase 3 Cohort 1: Placebo - MSODPhase 3 Cohort 1: Sarilumab 200mg IV - MSODPhase 3 Cohort 1: Sarilumab 400mg IV - MSODPhase 3 Cohort 1: Placebo - ImmunocompromisedPhase 3 Cohort 1: Sarilumab 200mg IV - ImmunocompromisedPhase 3 Cohort 1: Sarilumab 400mg IV - ImmunocompromisedPhase 3 Cohort 2: PlaceboPhase 3 Cohort 2: Sarilumab 800 mg IVPhase 3 Cohort 3: PlaceboPhase 3 Cohort 3: Sarilumab 800 mg IV
Day 1 (Baseline)117.70 ± 19.85121.25 ± 20.39121.06 ± 19.97127.64 ± 15.27124.18 ± 20.59124.76 ± 20.64114.59 ± 19.03110.40 ± 22.34104.19 ± 19.40121.88 ± 24.00120.55 ± 18.9399.00 ± 22.83111.20 ± 19.01115.75 ± 21.51122.00 ± 17.16111.50 ± 33.23
Day 4112.90 ± 20.72121.03 ± 20.83120.57 ± 21.82123.58 ± 16.89125.70 ± 20.59125.61 ± 20.74101.36 ± 16.90106.55 ± 21.22102.46 ± 20.43114.13 ± 15.57118.25 ± 21.6497.13 ± 22.68103.73 ± 19.49114.56 ± 17.00115.33 ± 16.15113.50 ± 38.89
Day 1599.66 ± 20.00104.70 ± 22.93107.87 ± 23.48112.15 ± 21.36106.27 ± 20.25113.43 ± 27.1191.16 ± 15.8595.21 ± 18.3090.88 ± 18.37106.75 ± 28.94111.00 ± 21.8791.86 ± 19.1592.85 ± 16.80109.43 ± 15.54103.40 ± 20.88101.50 ± 14.85
Day 2984.31 ± 15.0591.50 ± 18.0896.28 ± 19.5086.67 ± 17.6799.58 ± 22.4888.92 ± 22.7285.23 ± 10.8888.74 ± 13.2788.44 ± 15.13135.00 ± 096.00 ± 11.2785.20 ± 13.6899.40 ± 23.03106.29 ± 12.5998.50 ± 38.8982.50 ± 6.36
SecondaryMean Observed Platelet Count Across Study Days (Phase 2)
Time frame:
Days 1, 4, 15 and 29
Reported as:
Mean · 10^9 platelets/liter(L)
Mean Observed Platelet Count Across Study Days (Phase 2)
10^9 platelets/liter(L)Phase 2: PlaceboPhase 2: Sarilumab 200mg IVPhase 2: Sarilumab 400mg IV
Day 1 (Baseline)241.03 ± 102.22249.40 ± 100.55261.50 ± 94.51
Day 4314.86 ± 129.80304.94 ± 117.17319.89 ± 116.80
Day 15351.89 ± 155.08264.03 ± 116.22257.88 ± 118.01
Day 29313.12 ± 148.66306.87 ± 119.10312.14 ± 147.07
SecondaryMean Observed Platelet Count Across Study Days (Phase 3)
Time frame:
Days 1, 4, 15 and 29
Reported as:
Mean · 10^9 platelets/liter(L)
Mean Observed Platelet Count Across Study Days (Phase 3)
10^9 platelets/liter(L)Phase 3 Cohort 1: Placebo - CriticalPhase 3 Cohort 1: Sarilumab 200mg IV - CriticalPhase 3 Cohort 1: Sarilumab 400mg IV - CriticalPhase 3 Cohort 1: Placebo - SeverePhase 3 Cohort 1: Sarilumab 200mg IV - SeverePhase 3 Cohort 1: Sarilumab 400mg IV - SeverePhase 3 Cohort 1: Placebo - MSODPhase 3 Cohort 1: Sarilumab 200mg IV - MSODPhase 3 Cohort 1: Sarilumab 400mg IV - MSODPhase 3 Cohort 1: Placebo - ImmunocompromisedPhase 3 Cohort 1: Sarilumab 200mg IV - ImmunocompromisedPhase 3 Cohort 1: Sarilumab 400mg IV - ImmunocompromisedPhase 3 Cohort 2: PlaceboPhase 3 Cohort 2: Sarilumab 800 mg IVPhase 3 Cohort 3: PlaceboPhase 3 Cohort 3: Sarilumab 800 mg IV
Day 1 (Baseline)285.56 ± 120.77278.60 ± 112.15278.40 ± 120.16251.03 ± 109.74271.70 ± 109.63259.06 ± 115.47244.11 ± 103.10251.85 ± 105.45258.37 ± 100.32233.00 ± 74.04221.64 ± 84.86190.33 ± 77.23228.40 ± 121.12278.31 ± 130.65298.50 ± 114.86197.00 ± 22.63
Day 4328.20 ± 137.22318.16 ± 129.76311.42 ± 136.44324.57 ± 154.49348.96 ± 135.13330.84 ± 154.22276.70 ± 111.39275.84 ± 116.70268.18 ± 116.49244.88 ± 73.27261.00 ± 109.90225.47 ± 75.84267.80 ± 132.29318.25 ± 134.09421.17 ± 135.03294.00 ± 127.28
Day 15315.38 ± 143.62230.44 ± 100.71222.62 ± 100.21271.71 ± 124.32242.40 ± 82.25223.14 ± 102.57312.81 ± 155.88232.97 ± 115.44226.89 ± 110.91219.25 ± 77.89203.63 ± 47.37133.14 ± 59.74275.69 ± 150.11209.00 ± 92.41306.60 ± 108.91259.00 ± 39.60
Day 29284.02 ± 143.38270.88 ± 102.72248.60 ± 139.26264.67 ± 147.97238.67 ± 125.15182.58 ± 107.29332.73 ± 156.61310.52 ± 155.05279.31 ± 124.43267.00 ± 0281.00 ± 130.09181.25 ± 53.01265.00 ± 70.67235.71 ± 100.19272.00 ± 26.87373.00 ± 367.70
SecondaryMean Observed Total Bilirubin Values Across Study Days (Phase 2)
Time frame:
Days 1, 4, 15 and 29
Reported as:
Mean · micromole/liter (umol/L)
Mean Observed Total Bilirubin Values Across Study Days (Phase 2)
micromole/liter (umol/L)Phase 2: PlaceboPhase 2: Sarilumab 200mg IVPhase 2: Sarilumab 400mg IV
Day 1 (Baseline)12.07 ± 14.2011.96 ± 13.5912.24 ± 15.77
Day 412.44 ± 10.9011.87 ± 17.129.89 ± 11.10
Day 1513.75 ± 17.6312.43 ± 8.6914.16 ± 21.94
Day 2914.00 ± 19.847.87 ± 3.4411.40 ± 12.23
SecondaryMean Observed Total Bilirubin Across Study Days (Phase 3)
Time frame:
Days 1, 4, 15 and 29
Reported as:
Mean · umol/L
Mean Observed Total Bilirubin Across Study Days (Phase 3)
umol/LPhase 3 Cohort 1: Placebo - CriticalPhase 3 Cohort 1: Sarilumab 200mg IV - CriticalPhase 3 Cohort 1: Sarilumab 400mg IV - CriticalPhase 3 Cohort 1: Placebo - SeverePhase 3 Cohort 1: Sarilumab 200mg IV - SeverePhase 3 Cohort 1: Sarilumab 400mg IV - SeverePhase 3 Cohort 1: Placebo - MSODPhase 3 Cohort 1: Sarilumab 200mg IV - MSODPhase 3 Cohort 1: Sarilumab 400mg IV - MSODPhase 3 Cohort 1: Placebo - ImmunocompromisedPhase 3 Cohort 1: Sarilumab 200mg IV - ImmunocompromisedPhase 3 Cohort 1: Sarilumab 400mg IV - ImmunocompromisedPhase 3 Cohort 2: PlaceboPhase 3 Cohort 2: Sarilumab 800 mg IVPhase 3 Cohort 3: PlaceboPhase 3 Cohort 3: Sarilumab 800 mg IV
Day 1 (Baseline)11.79 ± 7.6612.02 ± 7.8212.99 ± 14.209.09 ± 4.179.93 ± 5.2710.12 ± 5.9510.94 ± 8.5716.89 ± 21.7716.56 ± 13.466.27 ± 2.5710.10 ± 9.907.30 ± 4.7710.79 ± 7.479.92 ± 5.939.98 ± 1.689.41 ± 1.21
Day 413.11 ± 13.1110.10 ± 6.3910.21 ± 8.619.53 ± 4.678.45 ± 5.438.38 ± 4.1614.57 ± 14.9310.94 ± 10.4513.98 ± 11.007.98 ± 6.1810.26 ± 8.126.96 ± 3.1112.43 ± 5.197.70 ± 5.1511.40 ± 4.559.41 ± 3.63
Day 1516.47 ± 37.1311.66 ± 8.0915.60 ± 48.788.66 ± 2.5411.07 ± 7.1519.37 ± 47.1413.20 ± 11.0210.69 ± 7.9314.26 ± 18.8519.24 ± 10.7616.37 ± 24.608.55 ± 2.6123.09 ± 45.4910.97 ± 3.5310.26 ± 4.5211.97 ± 2.42
Day 2911.66 ± 11.0011.74 ± 13.8619.24 ± 38.669.69 ± 0.9925.48 ± 38.2831.19 ± 71.389.69 ± 9.139.44 ± 9.4410.54 ± 8.1913.68 ± 03.42 ± 08.89 ± 3.714.27 ± 1.216.56 ± 2.5213.68 ± 14.517.70 ± 3.63
SecondaryMean Observed Aspartate Aminotransferase Values Across Study Days (Phase 2)
Time frame:
Days 1, 4, 15 and 29
Reported as:
Mean · International Units/Liter (IU/L)
Mean Observed Aspartate Aminotransferase Values Across Study Days (Phase 2)
International Units/Liter (IU/L)Phase 2: PlaceboPhase 2: Sarilumab 200mg IVPhase 2: Sarilumab 400mg IV
Day 1 (Baseline)58.58 ± 32.4057.88 ± 33.3560.39 ± 36.85
Day 462.52 ± 61.4190.01 ± 127.4278.34 ± 63.75
Day 1542.12 ± 25.17188.65 ± 941.9688.96 ± 329.04
Day 2976.00 ± 82.7840.69 ± 35.70100.05 ± 337.72
SecondaryMean Observed Aspartate Aminotransferase Values Across Study Days (Phase 3)
Time frame:
Days 1, 4, 15 and 29
Reported as:
Mean · IU/L
Mean Observed Aspartate Aminotransferase Values Across Study Days (Phase 3)
IU/LPhase 3 Cohort 1: Placebo - CriticalPhase 3 Cohort 1: Sarilumab 200mg IV - CriticalPhase 3 Cohort 1: Sarilumab 400mg IV - CriticalPhase 3 Cohort 1: Placebo - SeverePhase 3 Cohort 1: Sarilumab 200mg IV - SeverePhase 3 Cohort 1: Sarilumab 400mg IV - SeverePhase 3 Cohort 1: Placebo - MSODPhase 3 Cohort 1: Sarilumab 200mg IV - MSODPhase 3 Cohort 1: Sarilumab 400mg IV - MSODPhase 3 Cohort 1: Placebo - ImmunocompromisedPhase 3 Cohort 1: Sarilumab 200mg IV - ImmunocompromisedPhase 3 Cohort 1: Sarilumab 400mg IV - ImmunocompromisedPhase 3 Cohort 2: PlaceboPhase 3 Cohort 2: Sarilumab 800 mg IVPhase 3 Cohort 3: PlaceboPhase 3 Cohort 3: Sarilumab 800 mg IV
Day 1 (Baseline)58.54 ± 33.6754.73 ± 35.9960.61 ± 39.1551.54 ± 28.3558.58 ± 45.1947.80 ± 29.3861.13 ± 38.2377.66 ± 163.3457.68 ± 36.0247.00 ± 37.4447.36 ± 24.5235.47 ± 22.9658.77 ± 42.0358.33 ± 27.48114.00 ± 134.1736.50 ± 3.54
Day 460.21 ± 74.9369.30 ± 65.1078.29 ± 108.5752.79 ± 39.9066.47 ± 63.9576.77 ± 178.9765.39 ± 52.2794.76 ± 136.93124.83 ± 270.7858.00 ± 69.6551.33 ± 33.7252.93 ± 48.6876.73 ± 35.2475.88 ± 51.1574.50 ± 65.3132.50 ± 19.09
Day 1562.95 ± 131.4972.27 ± 232.2175.08 ± 162.6038.73 ± 20.8173.42 ± 152.57126.70 ± 312.3650.00 ± 37.3649.89 ± 46.5098.84 ± 276.99128.25 ± 180.1245.29 ± 26.3052.29 ± 43.1033.17 ± 9.6864.08 ± 58.9740.00 ± 41.8715.00 ± 4.24
Day 2952.76 ± 102.66163.83 ± 817.08363.69 ± 2565.7780.33 ± 65.90347.60 ± 982.8972.17 ± 86.3935.24 ± 21.5140.07 ± 25.6738.19 ± 29.8225.00 ± 020.00 ± 031.20 ± 16.6925.50 ± 13.4446.67 ± 39.8769.00 ± 57.9846.00 ± 42.43
SecondaryMean Observed Alanine Aminotransferase Values Across Study Days (Phase 2)
Time frame:
Days 1, 4, 15 and 29
Reported as:
Mean · International Units/Liter (IU/L)
Mean Observed Alanine Aminotransferase Values Across Study Days (Phase 2)
International Units/Liter (IU/L)Phase 2: PlaceboPhase 2: Sarilumab 200mg IVPhase 2: Sarilumab 400mg IV
Day 1 (Baseline)47.93 ± 34.7550.25 ± 36.6948.25 ± 30.38
Day 454.34 ± 42.1586.08 ± 148.4674.20 ± 78.45
Day 1555.00 ± 37.75106.17 ± 282.61121.58 ± 507.41
Day 2994.30 ± 112.3658.63 ± 48.9264.82 ± 78.90
SecondaryMean Observed Alanine Aminotransferase Values Across Study Days (Phase 3)
Time frame:
Days 1, 4, 15 and 29
Reported as:
Mean · International Units/Liter (IU/L)
Mean Observed Alanine Aminotransferase Values Across Study Days (Phase 3)
International Units/Liter (IU/L)Phase 3 Cohort 1: Placebo - CriticalPhase 3 Cohort 1: Sarilumab 200mg IV - CriticalPhase 3 Cohort 1: Sarilumab 400mg IV - CriticalPhase 3 Cohort 1: Placebo - SeverePhase 3 Cohort 1: Sarilumab 200mg IV - SeverePhase 3 Cohort 1: Sarilumab 400mg IV - SeverePhase 3 Cohort 1: Placebo - MSODPhase 3 Cohort 1: Sarilumab 200mg IV - MSODPhase 3 Cohort 1: Sarilumab 400mg IV - MSODPhase 3 Cohort 1: Placebo - ImmunocompromisedPhase 3 Cohort 1: Sarilumab 200mg IV - ImmunocompromisedPhase 3 Cohort 1: Sarilumab 400mg IV - ImmunocompromisedPhase 3 Cohort 2: PlaceboPhase 3 Cohort 2: Sarilumab 800 mg IVPhase 3 Cohort 3: PlaceboPhase 3 Cohort 3: Sarilumab 800 mg IV
Day 1 (Baseline)51.69 ± 37.3651.08 ± 35.8752.15 ± 36.6646.69 ± 34.0954.22 ± 42.2749.43 ± 39.9845.00 ± 35.0759.13 ± 96.7441.75 ± 29.4233.50 ± 18.4543.00 ± 31.8122.27 ± 25.5746.77 ± 31.4945.33 ± 40.77103.33 ± 153.1533.50 ± 30.41
Day 473.45 ± 139.0672.32 ± 60.2574.62 ± 77.0959.38 ± 51.0468.69 ± 51.4586.13 ± 146.9252.22 ± 52.8669.75 ± 102.6684.68 ± 152.7240.86 ± 26.6245.17 ± 23.3538.50 ± 45.6662.27 ± 33.2953.06 ± 44.57103.67 ± 174.3532.00 ± 28.28
Day 1571.09 ± 71.1179.98 ± 131.2193.82 ± 155.9852.60 ± 48.0697.73 ± 205.87101.00 ± 156.4262.11 ± 42.1564.80 ± 68.1198.31 ± 163.08257.25 ± 454.5766.14 ± 51.8947.57 ± 53.5345.83 ± 24.5285.75 ± 104.5624.33 ± 7.5114.00 ± 4.24
Day 2966.71 ± 107.2486.04 ± 155.72155.63 ± 759.3460.00 ± 36.37127.30 ± 173.3888.17 ± 127.3246.24 ± 48.8746.85 ± 28.1448.51 ± 39.4417.00 ± 039.00 ± 036.00 ± 32.9925.50 ± 0.7158.33 ± 33.6648.00 ± 12.7383.50 ± 85.56
SecondaryMean Observed Creatinine Values Across Study Days (Phase 2)
Time frame:
Days 1, 4, 15 and 29
Reported as:
Mean · micromole/liter (umol/L)
Mean Observed Creatinine Values Across Study Days (Phase 2)
micromole/liter (umol/L)Phase 2: PlaceboPhase 2: Sarilumab 200mg IVPhase 2: Sarilumab 400mg IV
Day 1 (Baseline)129.81 ± 142.13137.20 ± 148.58158.18 ± 242.13
Day 4153.12 ± 184.77151.86 ± 163.45164.62 ± 246.69
Day 15188.56 ± 260.81168.74 ± 201.28155.23 ± 163.50
Day 29147.52 ± 138.14138.02 ± 121.95118.56 ± 133.25
SecondaryMean Observed Creatinine Values Across Study Days (Phase 3)
Time frame:
Days 1, 4, 15 and 29
Reported as:
Mean · umol/L
Mean Observed Creatinine Values Across Study Days (Phase 3)
umol/LPhase 3 Cohort 1: Placebo - CriticalPhase 3 Cohort 1: Sarilumab 200mg IV - CriticalPhase 3 Cohort 1: Sarilumab 400mg IV - CriticalPhase 3 Cohort 1: Placebo - SeverePhase 3 Cohort 1: Sarilumab 200mg IV - SeverePhase 3 Cohort 1: Sarilumab 400mg IV - SeverePhase 3 Cohort 1: Placebo - MSODPhase 3 Cohort 1: Sarilumab 200mg IV - MSODPhase 3 Cohort 1: Sarilumab 400mg IV - MSODPhase 3 Cohort 1: Placebo - ImmunocompromisedPhase 3 Cohort 1: Sarilumab 200mg IV - ImmunocompromisedPhase 3 Cohort 1: Sarilumab 400mg IV - ImmunocompromisedPhase 3 Cohort 2: PlaceboPhase 3 Cohort 2: Sarilumab 800 mg IVPhase 3 Cohort 3: PlaceboPhase 3 Cohort 3: Sarilumab 800 mg IV
Day 1 (Baseline)122.64 ± 145.57141.97 ± 187.40121.75 ± 132.43109.14 ± 196.52174.92 ± 802.76111.63 ± 168.83187.93 ± 232.11308.63 ± 308.42280.83 ± 280.30259.01 ± 401.63265.36 ± 396.16401.87 ± 294.63103.19 ± 74.6078.79 ± 30.71108.73 ± 92.72497.25 ± 621.96
Day 4133.77 ± 144.10129.08 ± 145.08128.56 ± 127.4893.23 ± 151.97101.45 ± 129.88113.30 ± 152.19176.80 ± 160.17314.53 ± 352.59281.92 ± 310.48267.96 ± 479.59205.38 ± 249.38395.09 ± 246.34121.40 ± 84.3399.28 ± 96.7483.24 ± 62.60458.80 ± 576.33
Day 15151.06 ± 175.53136.98 ± 149.03120.96 ± 134.39151.11 ± 284.59175.09 ± 243.54111.99 ± 97.29160.94 ± 198.07179.87 ± 183.06170.10 ± 198.20142.32 ± 115.06137.46 ± 99.29270.39 ± 176.43116.96 ± 92.3486.06 ± 64.78136.49 ± 110.96311.61 ± 396.93
Day 29133.14 ± 140.37124.97 ± 124.62100.02 ± 107.10122.88 ± 161.56205.17 ± 269.33143.62 ± 98.50128.74 ± 191.15125.21 ± 128.22197.65 ± 655.3880.44 ± 0116.69 ± 32.20195.01 ± 108.7955.69 ± 15.1478.30 ± 40.1265.86 ± 11.88276.25 ± 346.92

Adverse events

Collected over From first dose of study drug to Day 60. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 2: Placebo24/90 (26.7%)39/90 (43.3%)20/90 (22.2%)
Phase 2: Sarilumab 200mg IV60/187 (32.1%)90/187 (48.1%)48/187 (25.7%)
Phase 2: Sarilumab 400mg IV49/180 (27.2%)84/180 (46.7%)44/180 (24.4%)
Phase 3 Cohort 1: Placebo - Critical59/170 (34.7%)89/170 (52.4%)24/170 (14.1%)
Phase 3 Cohort 1: Sarilumab 200mg IV - Critical70/242 (28.9%)119/242 (49.2%)57/242 (23.6%)
Phase 3 Cohort 1: Sarilumab 400mg IV - Critical114/338 (33.7%)183/338 (54.1%)83/338 (24.6%)
Phase 3 Cohort 1: Placebo - Severe9/70 (12.9%)11/70 (15.7%)0/70 (0%)
Phase 3 Cohort 1: Sarilumab 200mg IV - Severe12/140 (8.6%)23/140 (16.4%)0/140 (0%)
Phase 3 Cohort 1: Sarilumab 400mg IV - Severe21/137 (15.3%)30/137 (21.9%)8/137 (5.8%)
Phase 3 Cohort 1: Placebo - MSOD16/46 (34.8%)27/46 (58.7%)17/46 (37%)
Phase 3 Cohort 1: Sarilumab 200 mg IV - MSOD40/95 (42.1%)67/95 (70.5%)23/95 (24.2%)
Phase 3 Cohort 1: Sarilumab 400 mg IV - MSOD40/92 (43.5%)58/92 (63%)15/92 (16.3%)
Phase 3 Cohort 1: Placebo - Immunocompromised3/8 (37.5%)3/8 (37.5%)3/8 (37.5%)
Phase 3 Cohort 1: Sarilumab 200 mg IV - Immunocompromised4/12 (33.3%)6/12 (50%)5/12 (41.7%)
Phase 3 Cohort 1: Sarilumab 400 mg IV - Immunocompromised6/15 (40%)9/15 (60%)6/15 (40%)
Phase 3 Cohort 2: Placebo4/15 (26.7%)10/15 (66.7%)5/15 (33.3%)
Phase 3 Cohort 2: Sarilumab 800 mg IV3/16 (18.8%)5/16 (31.3%)7/16 (43.8%)
Phase 3 Cohort 3: Placebo1/6 (16.7%)1/6 (16.7%)1/6 (16.7%)
Phase 3 Cohort 3: Sarilumab 800 mg IV0/2 (0%)1/2 (50%)2/2 (100%)
Most frequent serious events
Showing 10 of 280
Most frequent serious events
EventPhase 2: PlaceboPhase 2: Sarilumab 200mg IVPhase 2: Sarilumab 400mg IVPhase 3 Cohort 1: Placebo - CriticalPhase 3 Cohort 1: Sarilumab 200mg IV - CriticalPhase 3 Cohort 1: Sarilumab 400mg IV - CriticalPhase 3 Cohort 1: Placebo - SeverePhase 3 Cohort 1: Sarilumab 200mg IV - SeverePhase 3 Cohort 1: Sarilumab 400mg IV - SeverePhase 3 Cohort 1: Placebo - MSODPhase 3 Cohort 1: Sarilumab 200 mg IV - MSODPhase 3 Cohort 1: Sarilumab 400 mg IV - MSODPhase 3 Cohort 1: Placebo - ImmunocompromisedPhase 3 Cohort 1: Sarilumab 200 mg IV - ImmunocompromisedPhase 3 Cohort 1: Sarilumab 400 mg IV - ImmunocompromisedPhase 3 Cohort 2: PlaceboPhase 3 Cohort 2: Sarilumab 800 mg IVPhase 3 Cohort 3: PlaceboPhase 3 Cohort 3: Sarilumab 800 mg IV
Acute respiratory failureRespiratory, thoracic and mediastinal disorders7/908/1874/18010/1706/24217/3381/704/1404/1371/463/952/920/80/120/150/150/161/61/2
AnaemiaBlood and lymphatic system disorders1/901/1874/1804/1703/2424/3380/700/1400/1370/461/951/920/80/121/153/151/160/60/2
COVID-19Infections and infestations3/9013/1875/18015/17019/24223/3380/702/1405/1375/4612/959/920/82/120/151/150/160/60/2
Septic shockInfections and infestations1/904/1872/1809/1706/24212/3380/701/1402/1370/464/955/920/80/120/150/152/161/60/2
Atrial fibrillationCardiac disorders1/901/1873/1803/1703/2424/3380/701/1400/1370/462/953/920/80/120/150/150/161/60/2
Pulseless electrical activityCardiac disorders0/901/1870/1803/1701/2422/3380/700/1400/1370/460/951/920/80/121/150/150/161/60/2
Acute kidney injuryRenal and urinary disorders5/909/1879/18010/17012/24210/3380/700/1401/1371/461/950/920/80/120/152/150/161/60/2
Deep vein thrombosisVascular disorders1/904/1879/1804/1708/24212/3380/700/1401/1371/461/952/920/80/120/150/150/161/60/2
COVID-19 pneumoniaInfections and infestations0/901/1870/1804/1703/2425/3382/700/1400/1371/462/953/920/80/120/152/151/160/60/2
Pneumonia bacterialInfections and infestations0/901/1873/1800/1703/2423/3380/700/1401/1370/461/952/920/80/120/152/150/160/60/2
Most frequent other events
Showing 10 of 23
Most frequent other events
EventPhase 2: PlaceboPhase 2: Sarilumab 200mg IVPhase 2: Sarilumab 400mg IVPhase 3 Cohort 1: Placebo - CriticalPhase 3 Cohort 1: Sarilumab 200mg IV - CriticalPhase 3 Cohort 1: Sarilumab 400mg IV - CriticalPhase 3 Cohort 1: Placebo - SeverePhase 3 Cohort 1: Sarilumab 200mg IV - SeverePhase 3 Cohort 1: Sarilumab 400mg IV - SeverePhase 3 Cohort 1: Placebo - MSODPhase 3 Cohort 1: Sarilumab 200 mg IV - MSODPhase 3 Cohort 1: Sarilumab 400 mg IV - MSODPhase 3 Cohort 1: Placebo - ImmunocompromisedPhase 3 Cohort 1: Sarilumab 200 mg IV - ImmunocompromisedPhase 3 Cohort 1: Sarilumab 400 mg IV - ImmunocompromisedPhase 3 Cohort 2: PlaceboPhase 3 Cohort 2: Sarilumab 800 mg IVPhase 3 Cohort 3: PlaceboPhase 3 Cohort 3: Sarilumab 800 mg IV
Staphylococcal infectionInfections and infestations0/900/1870/1800/1700/2420/3380/700/1400/1373/466/950/920/80/120/150/151/160/61/2
DyspnoeaRespiratory, thoracic and mediastinal disorders0/900/1870/1800/1700/2420/3380/700/1400/1370/460/950/920/80/120/150/150/160/61/2
Aspartate aminotransferase increasedInvestigations15/9030/18730/18016/17036/24236/3380/700/1400/13712/4612/9510/921/81/122/151/152/160/60/2
Liver function test increasedInvestigations0/900/1870/1800/1700/2420/3380/700/1400/1373/460/950/920/83/120/151/151/160/60/2
Alanine aminotransferase increasedInvestigations13/9038/18730/18019/17042/24251/3380/700/1408/1379/467/9511/921/81/121/151/150/160/60/2
Staphylococcal bacteraemiaInfections and infestations0/900/1870/1800/1700/2420/3380/700/1400/1370/460/950/920/81/120/150/150/161/60/2
Clostridium difficile colitisInfections and infestations0/900/1870/1800/1700/2420/3380/700/1400/1370/460/950/920/80/122/150/150/160/60/2
FungaemiaInfections and infestations0/900/1870/1800/1700/2420/3380/700/1400/1370/460/950/920/80/122/150/150/160/60/2
Fungal infectionInfections and infestations0/900/1870/1800/1700/2420/3380/700/1400/1370/460/950/921/80/120/150/150/160/60/2
Pseudomonas infectionInfections and infestations0/900/1870/1800/1700/2420/3380/700/1400/1370/460/950/921/80/120/150/150/160/60/2

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Phase 2: PlaceboPhase 2: Sarilumab 200mg IVPhase 2: Sarilumab 400mg IVPhase 3 Cohort 1: Placebo - CriticalPhase 3 Cohort 1: Sarilumab 200mg IV - CriticalPhase 3 Cohort 1: Sarilumab 400mg IV - CriticalPhase 3 Cohort 1: Placebo - SeverePhase 3 Cohort 1: Sarilumab 200mg IV - SeverePhase 3 Cohort 1 :Sarilumab 400mg IV - SeverePhase 3 Cohort 1: Placebo - MSODPhase 3 Cohort 1: Sarilumab 200mg IV - MSODPhase 3 Cohort 1: Sarilumab 400mg IV - MSODPhase 3 Cohort 1: Placebo - ImmunocompromisedPhase 3 Cohort 1: Sarilumab 200mg IV - ImmunocompromisedPhase 3 Cohort 1: Sarilumab 400mg IV - ImmunocompromisedPhase 3 Cohort 2: PlaceboPhase 3 Cohort 2: Sarilumab 800mg IVPhase 3 Cohort 3: PlaceboPhase 3 Cohort 3: Sarilumab 800mg IVTotal
Mean60.3 ± 13.457.1 ± 14.656.3 ± 14.760.1 ± 15.058.5 ± 13.761.8 ± 14.261.2 ± 13.961.3 ± 15.162.2 ± 15.359.9 ± 13.759.1 ± 12.461.1 ± 15.158.3 ± 11.957.7 ± 7.065.2 ± 8.048.6 ± 15.352.9 ± 14.761.5 ± 9.166.0 ± 7.159.7 ± 14.4
Sex: Female, Male
Sex: Female, Male(Participants)Phase 2: PlaceboPhase 2: Sarilumab 200mg IVPhase 2: Sarilumab 400mg IVPhase 3 Cohort 1: Placebo - CriticalPhase 3 Cohort 1: Sarilumab 200mg IV - CriticalPhase 3 Cohort 1: Sarilumab 400mg IV - CriticalPhase 3 Cohort 1: Placebo - SeverePhase 3 Cohort 1: Sarilumab 200mg IV - SeverePhase 3 Cohort 1 :Sarilumab 400mg IV - SeverePhase 3 Cohort 1: Placebo - MSODPhase 3 Cohort 1: Sarilumab 200mg IV - MSODPhase 3 Cohort 1: Sarilumab 400mg IV - MSODPhase 3 Cohort 1: Placebo - ImmunocompromisedPhase 3 Cohort 1: Sarilumab 200mg IV - ImmunocompromisedPhase 3 Cohort 1: Sarilumab 400mg IV - ImmunocompromisedPhase 3 Cohort 2: PlaceboPhase 3 Cohort 2: Sarilumab 800mg IVPhase 3 Cohort 3: PlaceboPhase 3 Cohort 3: Sarilumab 800mg IVTotal
Female21634259671112559512141344344530617
Male6912413811117522745818625545849111111321244
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Phase 2: PlaceboPhase 2: Sarilumab 200mg IVPhase 2: Sarilumab 400mg IVPhase 3 Cohort 1: Placebo - CriticalPhase 3 Cohort 1: Sarilumab 200mg IV - CriticalPhase 3 Cohort 1: Sarilumab 400mg IV - CriticalPhase 3 Cohort 1: Placebo - SeverePhase 3 Cohort 1: Sarilumab 200mg IV - SeverePhase 3 Cohort 1 :Sarilumab 400mg IV - SeverePhase 3 Cohort 1: Placebo - MSODPhase 3 Cohort 1: Sarilumab 200mg IV - MSODPhase 3 Cohort 1: Sarilumab 400mg IV - MSODPhase 3 Cohort 1: Placebo - ImmunocompromisedPhase 3 Cohort 1: Sarilumab 200mg IV - ImmunocompromisedPhase 3 Cohort 1: Sarilumab 400mg IV - ImmunocompromisedPhase 3 Cohort 2: PlaceboPhase 3 Cohort 2: Sarilumab 800mg IVPhase 3 Cohort 3: PlaceboPhase 3 Cohort 3: Sarilumab 800mg IVTotal
Hispanic or Latino165440597711519303012272113451021526
Not Hispanic or Latino59981058711916340808826464757105630994
Unknown or Not Reported153535244660113019822242215011341
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Phase 2: PlaceboPhase 2: Sarilumab 200mg IVPhase 2: Sarilumab 400mg IVPhase 3 Cohort 1: Placebo - CriticalPhase 3 Cohort 1: Sarilumab 200mg IV - CriticalPhase 3 Cohort 1: Sarilumab 400mg IV - CriticalPhase 3 Cohort 1: Placebo - SeverePhase 3 Cohort 1: Sarilumab 200mg IV - SeverePhase 3 Cohort 1 :Sarilumab 400mg IV - SeverePhase 3 Cohort 1: Placebo - MSODPhase 3 Cohort 1: Sarilumab 200mg IV - MSODPhase 3 Cohort 1: Sarilumab 400mg IV - MSODPhase 3 Cohort 1: Placebo - ImmunocompromisedPhase 3 Cohort 1: Sarilumab 200mg IV - ImmunocompromisedPhase 3 Cohort 1: Sarilumab 400mg IV - ImmunocompromisedPhase 3 Cohort 2: PlaceboPhase 3 Cohort 2: Sarilumab 800mg IVPhase 3 Cohort 3: PlaceboPhase 3 Cohort 3: Sarilumab 800mg IVTotal
American Indian or Alaska Native00011102010000000006
Asian920211310826135320100000113
Native Hawaiian or Other Pacific Islander00101011100100000006
Black or African American153231233965103525823232293320350
White39706474891272845491129253337821677
More than one race00000000000000000000
Unknown or Not Reported276563591021372951492140413635521709
CRP levels
CRP levels(milligrams per Liter (mg/L))Phase 2: PlaceboPhase 2: Sarilumab 200mg IVPhase 2: Sarilumab 400mg IVPhase 3 Cohort 1: Placebo - CriticalPhase 3 Cohort 1: Sarilumab 200mg IV - CriticalPhase 3 Cohort 1: Sarilumab 400mg IV - CriticalPhase 3 Cohort 1: Placebo - SeverePhase 3 Cohort 1: Sarilumab 200mg IV - SeverePhase 3 Cohort 1 :Sarilumab 400mg IV - SeverePhase 3 Cohort 1: Placebo - MSODPhase 3 Cohort 1: Sarilumab 200mg IV - MSODPhase 3 Cohort 1: Sarilumab 400mg IV - MSODPhase 3 Cohort 1: Placebo - ImmunocompromisedPhase 3 Cohort 1: Sarilumab 200mg IV - ImmunocompromisedPhase 3 Cohort 1: Sarilumab 400mg IV - ImmunocompromisedPhase 3 Cohort 2: PlaceboPhase 3 Cohort 2: Sarilumab 800mg IVPhase 3 Cohort 3: PlaceboPhase 3 Cohort 3: Sarilumab 800mg IVTotal
Mean192.537 ± 122.295191.997 ± 124.583195.037 ± 119.274167.476 ± 115.020187.573 ± 108.085179.085 ± 103.837111.933 ± 81.789127.811 ± 116.058129.355 ± 136.734205.978 ± 118.459235.395 ± 280.665232.924 ± 128.435141.207 ± 71.915203.356 ± 118.998185.740 ± 91.237226.846 ± 112.047212.920 ± 107.702177.334 ± 79.490258.081 ± 200.704180.010 ± 131.909
08

Study locations

62 sites
  • Regeneron Study Site
    Los Angeles, California 90095, United States
  • Regeneron Study Site
    Sacramento, California 95817, United States
  • Regeneron Study Site
    Santa Monica, California 90404, United States
  • Regeneron Study Site
    Aurora, Colorado 80045, United States
  • Regeneron Study Site
    Denver, Colorado 80206, United States
  • Regeneron Study Site
    New Haven, Connecticut 06520, United States
  • Regeneron Study Site
    Washington, District of Columbia 20010, United States
  • Regeneron Study Site
    Gainesville, Florida 32610, United States
  • Regeneron Study Site
    Orlando, Florida 32803, United States
  • Regeneron Study Site
    Tampa, Florida 33606, United States
  • Regeneron Study Site
    Atlanta, Georgia 30322, United States
  • Regeneron Study Site
    Decatur, Georgia 30033, United States
  • Regeneron Study Site
    Marietta, Georgia 30060, United States
  • Regeneron Study Site
    Chicago, Illinois 60611, United States
  • Regeneron Study Site
    Chicago, Illinois 60612, United States
  • Regeneron Study Site
    New Orleans, Louisiana 70112, United States
  • Regeneron Study Site
    Boston, Massachusetts 02111, United States
  • Regeneron Study Site
    Boston, Massachusetts 02114, United States
  • Regeneron Study Site
    Boston, Massachusetts 02215, United States
  • Regeneron Study Site
    Ann Arbor, Michigan 48109, United States
  • Regeneron Study Site
    Rochester, Minnesota 55905, United States
  • Regeneron Study Site
    Edison, New Jersey 08820, United States
  • Regeneron Study Site
    Hackensack, New Jersey 07601, United States
  • Regeneron Study Site
    Livingston, New Jersey 07039, United States
  • Regeneron Study Site
    Morristown, New Jersey 07960, United States
  • Regeneron Study Site
    Neptune, New Jersey 07753, United States
  • Regeneron Study Site
    Newark, New Jersey 07112, United States
  • Regeneron Study Site
    Teaneck, New Jersey 07666, United States
  • Regeneron Study Site
    Bronx, New York 10451, United States
  • Regeneron Study Site 1
    Bronx, New York 10461, United States
  • Regeneron Study Site 2
    Bronx, New York 10461, United States
  • Regeneron Study Site
    Bronx, New York 10467, United States
  • Regeneron Study Site
    Brooklyn, New York 11219, United States
  • Regeneron Study Site
    Buffalo, New York 14263, United States
  • Regeneron Study Site
    Elmhurst, New York 11373, United States
  • Regeneron Study Site 1
    Manhasset, New York 11030, United States
  • Regeneron Study Site 2
    Manhasset, New York 11030, United States
  • Regeneron Study Site
    New York, New York 10003, United States
  • Regeneron Study Site
    New York, New York 10016, United States
  • Regeneron Study Site 1
    New York, New York 10025, United States
  • Regeneron Study Site 2
    New York, New York 10025, United States
  • Regeneron Study Site
    New York, New York 10029, United States
  • Regeneron Study Site
    New York, New York 10032, United States
  • Regeneron Study Site
    New York, New York 10037, United States
  • Regeneron Study Site
    New York, New York 10065, United States
  • Regeneron Study Site
    New York, New York 10075, United States
  • Regeneron Study Site
    Stony Brook, New York 11794, United States
  • Regeneron Study Site
    Valhalla, New York 10595, United States
  • Regeneron Study Site
    Tulsa, Oklahoma 74104, United States
  • Regeneron Study Site
    Portland, Oregon 97213, United States
  • Regeneron Study Site
    Portland, Oregon 97239, United States
  • Regeneron Study Site
    Danville, Pennsylvania 17822, United States
  • Regeneron Study Site
    Philadelphia, Pennsylvania 19140, United States
  • Regeneron Study Site
    Scranton, Pennsylvania 18510, United States
  • Regeneron Study Site
    Wilkes-Barre, Pennsylvania 18711, United States
  • Regeneron Study Site
    Dallas, Texas 75246, United States
  • Regeneron Study Site
    Dallas, Texas 75390, United States
  • Regeneron Study Site
    Murray, Utah 84107, United States
  • Regeneron Study Site
    Falls Church, Virginia 22042, United States
  • Regeneron Study Site
    Richmond, Virginia 23298, United States
  • Regeneron Study Site
    Everett, Washington 98201, United States
  • Regeneron Study Site
    Renton, Washington 98055, United States
09

References and documents

Publications

  • Sivapalasingam S, Lederer DJ, Bhore R, Hajizadeh N, Criner G, Hosain R, Mahmood A, Giannelou A, Somersan-Karakaya S, O'Brien MP, Boyapati A, Parrino J, Musser BJ, Labriola-Tompkins E, Ramesh D, Purcell LA, Gulabani D, Kampman W, Waldron A, Ng Gong M, Saggar S, Sperber SJ, Menon V, Stein DK, Sobieszczyk ME, Park W, Aberg JA, Brown SM, Kosmicki JA, Horowitz JE, Ferreira MA, Baras A, Kowal B, Thomas DiCioccio A, Akinlade B, Nivens MC, Braunstein N, Herman GA, Yancopoulos GD, Weinreich DM. Efficacy and Safety of Sarilumab in Hospitalized Patients With Coronavirus Disease 2019: A Randomized Clinical Trial. Clin Infect Dis. 2022 Aug 24;75(1):e380-e388. doi: 10.1093/cid/ciac153. PubMed 35219277 ↗
  • Boyapati A, Wipperman MF, Ehmann PJ, Hamon S, Lederer DJ, Waldron A, Flanagan JJ, Karayusuf E, Bhore R, Nivens MC, Hamilton JD, Sumner G, Sivapalasingam S. Baseline Severe Acute Respiratory Syndrome Viral Load Is Associated With Coronavirus Disease 2019 Severity and Clinical Outcomes: Post Hoc Analyses of a Phase 2/3 Trial. J Infect Dis. 2021 Dec 1;224(11):1830-1838. doi: 10.1093/infdis/jiab445. PubMed 34496013 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — All IPD that underlie publicly available results will be considered for sharing

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification

Access criteria: Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., FDA, EMA, PMDA, etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2020 to primary completion in Jul 2020, 4 months.

Results were first posted in Sep 2021, 1 year 1 month after primary completion.

Of 73 industry-sponsored phase 2/3 interventional studies under COVID-19, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 18. This study's 4 months is below that.

Counting every sponsor, half of 168 studies reached it within 11 months; a quarter within 5 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2020
First posted
Mar 19, 2020
StartActual
Mar 18, 2020
Primary completionActual
Jul 24, 2020
CompletionActual
Sep 2, 2020
Results first posted
Sep 23, 2021
Last update
Sep 23, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04315298
Collaborators
Sanofi
Responsible party
Sponsor
First posted
Mar 19, 2020
Start date
Mar 18, 2020
Primary completion
Jul 24, 2020
Completion
Sep 2, 2020
Results posted
Sep 23, 2021
Last update
Sep 23, 2021

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sarilumab

Start the discussion